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The genes of the human 0-globin locus are located on chromosome 11 in the order
of their expression during development: 5'

E,

y, 0 3'. During development, silencing of

the 5' gene occurs with activation of the immediate 3' gene. This process occurs twice
and is termed hemoglobin switching. The exact mechanism(s) of this process have not
been fully described. Herein, we describe a role for DNA methylation and methyl binding
domain protein 2 in the transcriptional regulation of the human embryonic and fetal beta
type globin genes. Adult mice containing the entire human 0-globin locus as a yeast
artificial chromosome ( P A C ) express very low levels of the fetal y-globin gene.
However, treatment of adult OYAC transgenic mice with the DNA methyltransferase
inhibitor, 5-azacytidine, induces a >lo-fold increase y-globin mRNA levels. In addition,

...

Xlll

PYAC transgenic mice null for methyl binding domain protein 2 (MBD2) express a
similar level of y-globin niRNA. DNA niethylation and MBD2 appear to induce y-globin
expression via the same pathway(s), as treatment of MBD2 null PYAC transgenic mice
do not show an additive boost in y-globin expression. MBD2 does not bind to the yglobin promoter region in vivo indicating MBD2 mediated transcriptional silencing does
not occur by recruitment of transcriptional repression complexes to the y-globin gene
promoter. Additionally, these transgenic mice contain only the 5' portion of the 0-globin
locus through the c-globin, and do not express the c-globin genes as adults. However,
treatment with 5-azacytidine or loss of MBD2 induces expression of the c-globin gene in
adult transgenic mice. A similar induction of c-globin is seen in PYAC transgenic mice
under the same conditions. The level of expression of the c-globin gene is much lower
than the y-globin gene, indicating the powerful effect of the cis elements mediating
transcriptional repression of the c-globin gene. These studies indicate DNA methylation
and MBD2 contribute to the transcriptional repression of the human embryonic and fetal
@-typeglobin genes. Additionally, MBD2 has been identified as a potential target for the
therapeutic induction of fetal hemoglobin for the treatment of henioglobinopathies.

Chapter 1 : Introduction

The Human P-globin Locus

The human P-globin locus is located on chromosome 11 and the genes of the
locus encode the 0 chain of hemoglobin. The genes are positioned in the order of their
expressioii during development: 5'

E,

y, 6, and 3' (Figure 1 and 2). Two switches in

globin gene expression occur during development. The first occurs during the switch
from embryonic (primitive) to definitive hematopoiesis at 5 weeks post-conception. At
this time, y-globin replaces €-globin as the major 0-chain subunit. This time also marks a
change in the site of hematopoiesis from the yolk sac to the fetal liver. At the time of
birth, the second switch takes place whereby 0-globin replaces y-globin. By birth, the
bone marrow has become the primary site of hematopoiesis.
High level globin gene expression at all stages of development is regulated at
least in part by the locus control region (LCR). The LCR acts as an enhancer, resides 620 kb upstream of the €-globin gene, and consists of five DNase I hypersensitive sites
(HS1-5) (Stamatoyannopoulos and Grosveld, 2001). In addition, it confers copy-number

LCR
5 4 3 2 1
Human P-globin locus

Murine P-globin locus
Figure 1: The human and murine P-globin loci. The top picture depicts the human Pglobin locus while .the bottom depicts the murine P-globin locus. Numbers and arrows
indicate the position of DNase I hypersensititve sites wi.thin the locus control region
(LCR). The black boxes are the positions of the genes within each locus.

Figure 2: 6-type globin chain switching during development. This graph depicts the
switch in expression of 6-type globin genes during development (Harju et al., 2002).

dependent position-independent expression of a linked gene in transgenic mice (Fraser
and Grosveld, 1998; Grosveld et al., 1987).
The mouse has been a useful model system for the study of globin gene
regulation. In mice, the first switch in globin gene expression takes place at day 10.5
post-conception, when erythropoiesis shifts from the yolk sac to the fetal liver (Chada et
al., 1986; Farace et al., 1984). The mouse yolk sac contains erythroblasts of primitive
hematopoiesis and expresses the ~y (orthologous to the human E)and phl (orthologous to
the human y) globin genes. Unlike its orthologue, phl is only expressed in the cells of
primitive hematopoiesis. The fetal liver is the site of definitive hematopoiesis and
contains erythroblasts expressing the adult globin genes &major and 0-minor. Unlike the
human locus, the genes of the mouse 0-globin locus are not expressed in the order of their
position on the chromosome with phl expression coming first, followed by ~y expression
(Kingsley et al., 2005). However, mouse 0-type globin genes undergo a similar switching
program as is seen during human development (Figure 3). Interestingly, mice lack a fetal
&type globin gene as neither the ~y gene nor the phl gene is expressed in the fetal liver.
Nevertheless, due to evolutionary conservation, the mouse allows for the study of human
globin gene switching. Transgenic mice containing 70 to 248 kb constructs of the entire
human @-globinlocus as ligated cosmids, yeast artificial chromosomes (YACs), bacterial
artificial chromosomes (BACs), and phage artificial chromosomes (PACs) show correct
temporal expression patterns of the human genes during mouse development (Gaensler et
al., 1993; Imam et al., 2000; Peterson et al., 1993a; Peterson et al., 1993b; Peterson et al.,
1997; Peterson et al., 1998; Porcu et al., 1997; Strouboulis et al., 1992) (Figure 3). These

Days

Figure 3: Endogenous and human @-typeglobin switching in whole locus transgenic
mice. This graph depicts the changes in 6-type globin gene expression during
development. The y-axis on the left half depicts the level of human @-globinexpression
in transgenic mice containing the entire human P-globin locus as a yeast artificial
chromosome during development. The y-axis on the right depicts the level of
endogenous mouse 6-type globin expression during development (Gaensler et al., 1993).

transgenic mice express the fetal y-globin gene in the fetal liver, but it is not expressed as
highly as the human P-globin gene. The €-globin gene is expressed solely in the yolk sac
during primitive erythropoiesis. Expression of the y-globin gene begins in the yolk sac
during primitive erythropoiesis and continues into the definitive cells of the fetal liver,
finally switching off around day 17. Expression of the 0-globin gene begins at day 12 in
the fetal liver and is the only gene expressed in the adult. The ability of the mouse to
correctly regulate human P-globin transgenes has had a profoulid impact upon the study
of globin gene regulation. Through mutation, truncation, and rearrangement, insight has
been gained on the impact of cis regulatory elements within the P-globin locus. In
addition, the effects of gene overexpression or gene knock-out on globin gene regulation
have been studied.

Globin Gene Regulation

The globin genes each consist of three exons and two introns. Tissue specific
developmental regulation is achieved through the interaction of transcription factors and
regulatory elements flanking each gene and elements located at a distance from the genes.
~ r a n s ~ e nmice
i c derived from two different human €-globin constructs express .the gene
during primitive erythropoiesis, but fail to express upon definitive erythropoiesis (Raich
et a]., 1990; Shih et al., 1990). Thus, all elements necessary for developmentally correct
expression and silencing of €-globin gene silencing are located within the constructs used
in these studies, a mechanism termed autonomous silencing. The mechanism for y-globin

gene silencing differs slightly, as it is regulated partially by autonomous silencing and
partially by competition with other globin genes for upstream enhancer activity. When
attached to the LCR in the context of a transgenic mouse, y-globin mRNA is highly
expressed during the embryonic and fetal stages of development and is silenced in adult
mice. However, detectable levels of y-globin mRNA are seen in adult mice (Behringer et
al., 1990; Enver et al., 1989; Enver et al., 1990). When linked to a P-globin construct, the
y-globin gene becomes completely silenced in adult transgenic mice (Behringer et al.,
1990; Enver et al., 1990). Thus the y-globin gene is not completely silenced
autonomously and is dependent upon competition with other downstream globin genes
for complete silencing.
Specific cis elements have been investigated for their role in the autonomous
silencing of the e-globin gene. The first element discovered was located between -177
and -392 bp relative to the mRNA initiation site using a transfection assay (Cao et al.,
1989). Deletion of a region between -182 and -467, relative to the transcription start site,
in transgenic mice corroborated this finding (Raich et al., 1992). The region includes
three binding sites important for silencing: a GATA site at -208, a YY 1 site at -269, and a
CACCC motif at -379 (Peters et al., 1993; Raich et al., 1995). Interestingly, the GATA
site seems to act as a silencing motif. Disruption of the GATA site at -208 leads to eglobin expression in adult transgenic mice (Raich et al., 1995). Furthermore,
overexpression of GATA-1 in K562 cells and transgenic mice leads to €-globin
suppression (Ikonomi et al., 2000; Li et al., 1997). Mutations of the YY 1 site and
CACCC element lead to low levels of e-globin in adult transgenic mice (Raich et al.,

1995). The -182 to -467 silencer was studied using a 2.5kb micro-LCR and a 3.7 kb
EcoRI fragment of the e-globin gene (Raich et al., 1992). Different results were seen
upon deleting a fragment from -179 to -304 in the context of a yeast artificial
chromosome (Liu et al., 1997). The deletion included the YY 1 and GATA binding sites
previously defined as silencing elements. Transgenic mice harboring the YAC deletion
construct failed to express e-globin during primitive erythropoiesis and displayed reduced
y-globin expression at the same time (Liu et al., 1997). These data indicate the region
may act as an activator during development. This work shows the importance of using the
complete globin locus to study the autonomous silencing of the e-globin gene, and, in
addition, that other silencing elements may be present. In fact, two inverted direct repeats
of a short motif analogous to DR-1 binding sites for non-steroid nuclear hormone
receptors located in the region of the CCAAT box have been found to act as e-globin
silencers (Filipe et al., 1999; Tanimoto et al., 2000). Mutation of the 5' DR and both DRs
in the context of YAC transgenic mice leads to e-globin expression at levels of -1 and
4.5% relative to yolk sac expression levels, respectively (Tanimoto et al., 2000). This is
almost four times more induction than was seen when comparing the -182 to -467
deletion mice to wild type mice at 11 dpc (4.5% vs. 1.4%) (Raich et al., 1990; Raich et
al., 1992). Characterization of MEL cell nuclear extracts identified a novel complex,
DRED (direct repeat erythroid definitive), that binds to the inverted DRs only during
definitive erythropoiesis (Tanimoto et al., 2000). Further characterization of the complex
showed it to contain the nuclear orphan receptors TR2 and TR4 as a heterodimer (Tanabe
et al., 2002). The autonomous silencing of the human e-globin gene has been mapped to

four regulatory regions. Deletions or point mutations in these regions lead to adult
expression in the context of transgenic mice. The regions include, relative to the cap site,
-3000, between -2000 and -460, -460 to -180, and the proximal promoter (Li et al.,
1998a; Li et al., 1998b; Raich et al., 1995; Wada-Kiyama et al., 1992). However, none of
these elements is able to restore expression to levels seen in the yolk sac and, in addition,
no studies have been undertaken where multiple silencing elements have been eliminated.
This suggests that additional silencing elements are or there are other mechanisms of
silencing. In addition, factors specific for primitive erythropoiesis may be required to
achieve high levels of €-globin expression in the adult.
Unlike the €-globin gene, the y-globin gene is regulated by a combination of
autonomous silencing and competition. In transgenic mice made from a construct
containing portions of the LCR, both the y-globin gene and the 0-globin gene show
correct expression profiles during development (Behringer et al., 1990; Enver et al.,
1990). In contrast, mice containing the LCR and only the y-globin gene show incorrect
developmental regulation of the y-globin gene, since the y-globin gene is expressed in
adult mice (Behringer et al., 1990; Enver et al., 1989). These data indicate that the
presence of the 0-globin gene is needed to silence the y-globin gene during development,
presumably by competing for LCR-mediated enhancer activity. However, another study
using a different LCR-y-globin gene construct showed the correct developmental
silencing of the y-globin gene in the absence of other competing globin genes,
illuminating an autonomous silencing mechanism (Dillon and Grosveld, 1991). These
differences may be accounted for by the different constructs used in each study. Despite

these contradictory studies, it is generally accepted that both autonomous silencing and
competition each contribute to some degree to y-silencing during development.
Sequences within the pron~oterplay a crucial role in y-globin gene regulation. This point
is illustrated when looking at non-deletional mutants of hereditary persistence of fetal
hemoglobin (HPFH). Individuals wi.th HPFH express increased levels of fetal
hemoglobin as adults due to either genetic deletions or point mutations. Many of the
described point mutations of HPFH are due to single base pair substitutions in the yglobin promoter region (Table 1). Thus, the promoter region of the y-globin gene
contains important regulatory elements for maintaining y-globin gene suppression. The
two identical y-globin gene promoters each contain a canonical TATA box, a duplicated
CAAT box within a 27 bp segment, and a single CACCC box. Located between the
CAAT box and TATA box is a G-rich sequence possessing a binding activity called stage
selector protein (SSP) (307, 308). Mutation of the SSP binding site results in downregulation of the y-globin gene only when competing for the P-globin gene during the
second switch (Ristaldi et al., 2001). There are 2 CpG dinucleotides within the SSP
binding site, the stage selector element (SSE), at -55 and -50 relative to the transcription
start site. When these sites are methylated, Spl binds more readily than SSP. These data
indicate that SSP may bind the SSE as an activator while Spl may mediate repression of
the y-globin gene when the SSE is methylated, as is seen in adult erythroid cells
(Humphries et al., 1985). However, mice that contain the human P-globin locus but lack
functional Spl still express the y-globin gene, indicating that it is not functionally
important in vivo or that another factor can compensate for its loss (Marin et al., 1997).

Type and Ethnic Group

Mutation

HbF%
0.5-1

Normal
Japanese

GY-114c to^

11-14

Australian

GY-114c to G

8.6

BlackJSardinian

Gy-175 T to C

17-30

Tunician

Gy-200 +C

18-49

Black

Gy-202 C to G

15-25

Georgian

A y _ 1 1 4 to^
~

3-6.5

Black

A

30-32

Greek

*y-l14~to~

10-20

Cretan

Ay-158 C t o T

2.9-5.1

Black

Ay-175 T to C

36-41

Brazilian

A

y-195 C to G

4.5-7

ChineseIItalian

Ay-196 C to T

14-21

British

Ay-198 T to C

3.5-10

Georgian

A y-202

y- 114 to - 102 deleted

C to T

1.6-3.9

Table 1: List of non-deletional mutations of hereditary persistence of fetal hemoglobin
(Stamatoyannopoulos and Grosveld, 2001).

Mutation of the CACCC and TATA boxes in transgenic mice and transfected cells
interferes with competition and leads to an increase in 0-globin transcription at the
expense of the y-globin gene (Sargent et al., 1999; Sargent and Lloyd, 2001). The
CACCC box is the binding site for the zinc finger Kriippel like proteins. The erythroid
specific EKLF is crucial for P-globin activation and mice null for EKLF are embryonic
lethal due to severe anemia (Nuez et al., 1995; Perkins et al., 1995). EKLF is specific for
0-globin gene expression, despite the fact that both the y- and c-globin genes possess
CACCC boxes. Therefore, it was postulated that there exists a CACCC-binding factor
that specifically enhances E-and/or y-globin expression during development. However,
given the large number of known KLFs, no factor specific y-globin expression has
emerged (Zhang et al., 2005). However, KLF2 has emerged as an activator of the Eglobin gene, but not .the y-globin gene, indicating that another KLF or redundancy plays a
role in regulation of the y-globin by the CACCC box (Basu et al., 2005). Similar to the E globin gene, DRED mediated transcriptional repression at DR elements of the y-globin
gene has been described (Omori et al., 2005). In addition, a silencer element has been
mapped using transgenic mice to -378 to -730 relative to the transcription start site
(Stamatoyannopoulos et al., 1993). Cis elements located within the promoters of both the
human E-and y-globin genes contribute to the transcriptional regulation of the genes
during development.
Mechanisms for y-globin transcriptional repression have also been postulated to
occur at sites distant from the y-globin gene region. Increased expression of fetal
hemoglobin in the absence of any known deletional or non-deletional HPFH mutation has

been described. Mapping studies have linked regions of chromosome 6, 8, and X as
potential modifiers of y-globin expression (Chang et al., 1995; Gamer et al., 2004; Thein
and Craig, 1998; Wyszynski et al., 2004). Potential candidate genes in these regions
include Hbsll, GGH, DEPDC2, PIK3C2A, GPM6B, TSPYLI, and ZHX2. Thus,
regions outside of the y-globin gene may contribute to the transcriptional silencing of the
y-globin gene during development.

DNA Methylation

Epigenetic phenomena are biological processes that cause heritable changes in
gene expression without affecting the sequence of the gene itself. DNA methylation is the
prototypic epigenetic modification involving the addition of a methyl group to the carbon
5 position of the cytosine ring in a CpG dinucleotide by a DNA methyltransferase
(DNMT). Cytosine is the only base known to be methylated in eukaryotic DNA.
However, methylated cytosine is highly unstable and mutagenic. The number of CpG
dinucleotides is estimated to be 20% of what would be expected based on the base
composition of DNA owing to the spontaneous deamination of methylated cytosine to
thymine (Bird, 1980). Regions of the genome containing the expected frequency of CpG
dinucleotides have been termed "CpG islands." They are defined as regions that range
from 200 bases to several kilobases in length, with a G + C content greater than 50%, and
having a ratio of CpG to GpC greater than 0.6 (Gardiner-Garden and Frommer, 1987).

These CpG islands are believed to represent regions of the genome that have remained
unrnethylated and thus spared from the deamination process.
The DNA methyltransferase enzymes catalyze the addition of a methyl group to
the CpG dinucleotide. DNA methyltransferase 1 (DNMTl) is considered the maintenance
methyltransferase as it preferentially methylates hemi-methylated DNA during S-phase
(Leonhardt et al., 1992). DNMT3a and 3b preferentially methylates unmethylated DNA
and are considered to be "de novo" methyltransferases (Yokochi and Robertson, 2002).
The importance of DNA methylation is clearly evident in the embryonic lethal phenotype
of DNMTl or DNMT3 knock-out mice (Li et al., 1992; Okano et al., 1999).
Often there exists an inverse correlation between the level of DNA methylation
and transcriptional activity: hypennethylated regions of DNA are transcriptionally silent
and hypomethylated regions are active. The exact mechanism of DNA methylation
induced transcriptional silencing has not been completely discerned, but mechanisms
have been proposed (Singal and Ginder, 1999). One mechanism involves direct inhibition
of factor binding. AP-2, cMycIMym, the cyclic AMP-dependent activator CREB, E2F,
and NF-KBhave been shown to have impaired binding upon DNA methylation. On the
contrary, many transcription factor binding sites lack CpGs and some factors (Spl and
CTF) can bind regardless of methylation status (Tate and Bird, 1993).
A second mechanism involves the binding of transcriptional repressors directly to
methylated DNA. The discovery of a family of proteins, the methyl-CpG binding proteins
(MCBP), that specifically bind to methylated DNA has led to the theory that these
proteins act as the mediators of transcriptional repression by DNA methylation (Chen et

al., 2003; Hutchins et al., 2002; Lin and Nelson, 2003; Magdinier and Wolffe, 2001;
Sarraf and Stancheva, 2004; Zucker et al., 1983). There are currently six well
characterized MCBPs, five of which possess a distinct domain, the Methyl-CpG Binding
Domain (MBD) that is necessary and sufficient for binding of the proteins to methylated
DNA: MeCP2, MBD1, MBD2, MBD3, and MBD4 (Nan et al., 1993). The sixth protein,
Kaiso, binds to methylated DNA via its zinc-finger domains and lacks a true MBD
(Daniel et al., 2002).
MBD2 binds more avidly to methylated DNA in vitro as CpG density increases,
however it has been shown to bind to as few as three methylated CpGs in vitro (Fraga et
al., 2003). MBD2 was identified in the purification of the MeCP-1 complex, the first
methyl-CpG specific binding activity to be described (Feng and Zhang, 2001). This
protein complex consists of MBD2 and the Nucleosome Remodeling and Deacetylation
(NuRD) complex: Mi-2, MTA1, MTA2, MBD3, HDAC1, HDAC2, RbAp46, RbAp48.
Targeted knock-out of the MBD2 gene in mice generates a mild phenotype consisting of
a decrease in maternal-nurturing of pups (Hendrich et al., 2001). Loss of MBD2 is also
associated with dysregulation of the IL-4 gene in Thl and Th2 lymphocytes (Hutchins et
al., 2002). In addition, lack of MBD2 appears to prevent intestinal tumorigenesis in a
mouse model (Sansom et al., 2003). However, there are no other genes known to be
primarily regulated by MBD2 in non-cancerous cells.
MeCP2 is able to bind to a single symmetrically methylated CpG (Meehan et al.,
1992). MeCP2 contains a transcriptional repression domain (TRD) and has been shown
to interact with the Sin3a transcriptional repression complex (Nan et al., 1997). However,

this interaction is unstable, but a stable interaction between MeCP2 and Brahma, a
component of the SWVSNF nucleosome remodeling complex, has been reported
(Harikrishnan et al., 2005; Klose and Bird, 2004). In addition, MeCP2 recruits histone
methyltransfersase activity to the H19 gene (Fuks et al., 2003). MeCP2, unlike MBD2,
shows sequence specificity as it preferentially binds to CpGs with adjacent AIT tracks
(Klose et al., 2005). Mice null for MeCP2 have a severe phenotype similar to Rett
Syndrome, a human neurodevelopmental disorder leading to loss of voluntary movement
(Guy et al., 2001). Specifically, the Bdnf and D1x5 genes have been shown to be
regulated by MeCP2 in vivo (Chen et al., 2003; Horike et al., 2005; Martinowich et al.,
2003).
MBDl has been identified as a critical conlponent of an S-phase specific complex
that propagates the DNA methylation signal into dimethylation of lysine 9 of histone H3
during DNA replication (Sarraf and Stancheva, 2004). In addition, mice lacking
functional MBDl have deficits in hippocampal function (Zhao et al., 2003). MBD3 is a
core component of the NuRD complex and has been shown to associate with MBD2,
Ikaros, GATAI, and FOG (Hong et al., 2005; Kim et al., 1999; Rodriguez et al., 2005;
Zhang et al., 1999). MBD4 functions as a mismatch-specific T/U DNA glycosylase,
recognizing the product of spontaneous deamination of a methyl-CpG dinucleotide and
excising it (Hendrich et al., 1999). The Kaiso factor contains a transcriptional repressor
domain in addition to a zinc finger domain that confers sequence specificity, but lacks an
MBD (Prokhortchouk et al., 2001). Kaiso has been reported to interact with the N-Cor
complex to mediate DNA methylation dependent repression of the MTA2 gene (Yoon et

al., 2003). The zinc fingers of Kaiso can bind methylated DNA or the Kaiso binding site
(Daniel et al., 2002). No Kaiso knock-out mice have been generated, but the Kaiso gene
has been shown to be essential for Xenopus developn~ent(Ruzov et al., 2004).
MCBPs appear to be most crucial to neural development as genetic knock-out of
MBD2, MeCP2, and MBD1 all display a neural deficit phenotype. Knock-out of these
proteins is not lethal, unlike the DNMT knock-outs, suggesting each MCBP regulates
only a sub-set of genes or that MCBPs can compensate for each other. MBD2 has been
shown to bind to MeCP2 sites after knock-down of MeCP2, however, MeCP2 was unable
to bind to MBD2 sites after knock-down of MBD2 (Klose et al., 2005). Thus, MeCP2 has
more sequence specificity for binding methylated CpGs than MBD2. This may account
for the more severe phenotype of M ~ C null
P ~mice versus MBD2 null mice.
Interestingly, mice null for MBD3 are embryonic lethal (Hendrich et al., 2001). MBD3 is
a core component of the NuRD complex. The NuRD complex is a transcriptional
repression coniplex shown to interact with many proteins including MBD2. Thus, loss of
a key transcriptional repression complex is more severe than loss of a single MCBP. In
the absence of a MCBP, complexes such as NuRD are still able to interact with other
MCBPs. Therefore, the only genes dysregulated will be those that possess sequence
specific binding sites. On the other hand, loss of a transcriptional repression complex, for
example NuRD in the absence of MBD3, cannot be compensated for by another MCBP.
This may account for the phenotypic differences between MCBP knock-out mice and
MBD3 knock-out mice.

DNA Methylation and Globin Gene Regulation

DNA methylation was first hypothesized to play a role in gene regulation over 30
years ago (Holliday and Pugh, 1975; Riggs, 1975; Scarano, 1971). The first correlation
between transcriptional activity and DNA methylation was seen in chicken adult red
blood cells (McGhee and Ginder, 1979). Subsequently, similar results were seen in other
species (Atweh et al., 2003; Mavilio et al., 1983; Shen and Maniatis, 1980; van der Ploeg
and Flavell, 1980). These studies came to the same conclusion that actively transcribed
genes were in general hypomethylated around the promoter whereas silent genes were
hyperrnethylated. The globin genes were the first genes shown to be regulated in part by
DNA methylation and were among the first genes shown to be up-regulated by the
DNMT inhibitor 5-azacytidine, a cytosine analogue that incorporates into DNA and
covalently binds to DNMTs leading to their inhibition. 5-azacytidine was first shown to
increase fetal hemoglobin (HbF, y2@)in anemic baboons (DeSimone et al., 1982).
Similar induction of silenced embryonic and fetal globin genes by 5-azacytidine has been
reported in chickens, MEL cells, MEL cells containing human chromosome 11, and mice
harboring a YAC transgene (Atweh et al., 2003; Ginder et al., 1984; Ley et al., 1984;
Pace et al., 1994; Zucker et al., 1983). Taken together, these results indicate DNA
methylation plays a role in globin gene silencing during development. In addition,
methylation of the avian embryonic p-globin gene inversely correlates with its expression
during development (Singal et al., 1997).

Interestingly, co-administration of 5-azacytidine with the short chain fatty acid,
butyrate, was shown to synergistically increase expression of fetal hemoglobin in
baboons and err~bryonicp-globin in chickens versus 5-azacytidine treatment alone
(Constantoulakis et al., 1989; Ginder et al., 1984). A similar effect, though less
pronounced, was seen in mice harboring a PYAC transgene (Pace et al., 1994). Short
chain fatty acids (SCFA), among other functions, inhibit histone deacetylases (HDACs)
(Swank and Stamatoyannopoulos, 1998). The synergistic increase in globin gene
expression upon treatment with 5-azacytidine and SCFAs is likely due to the colocalization of HDACs with methyl binding complexes. A methyl CpG binding complex
has been shown to bind the p-globin promoter and proximal transcribed region (Singal et
al., 2002). Mass spectrometry analysis of the biochemically purified complex showed it
to contain both MBD2 and HDAC2 (Kransdorf and Ginder, 2004). MBD2 was further
shown to bind the p-globin promoter and proximal transcribed region in vivo by
chromatin immunoprecipitation assay (ChIP). Finally, this complex differs in
biochemical make-up from MeCPl and shows a preference for the p-globin proximal
transcribed region versus the CG11 construct used to purify MeCPl. This is evidence that
sequence specific binding of MCBPs may in part be determined by the biochemical
make-up of the complex it interacts with in a cell and tissue specific manner. Taken
together, these results indicate a complex interaction between DNA methylation, histone
acetylation, and histone methylation may be at work to regulate globiii gene expression.

Induction of Silenced Globin Genes

Short chain fatty acids alone have shown mixed results in the ability to induce
globin gene expression. Both sodium butyrate and alpha amino butyric acid were unable
to induce expression of silenced globin genes in anemic chickens or PYAC transgenic
mice (Ginder et al., 1984; Pace et al., 1994). However both sodium butyrate and
proprionate were able to induce mouse ~y expression in MEL cells (Little et al., 1995).
Increased levels of y-globin mRNA have been seen in patients receiving SCFA treatment
and in children with metabolic disorders leading to increased levels of SCFAs in the
serum (Collins et al., 1994; Collins et al., 1995; Little et al., 1995; Olivieri et al., 1997;
Perrine et al., 1993; Sher et al., 1995). Treatment of m A C transgenic mice and baboons
with various short chain fatty acid derivates (SCFAD) induced y-globin mRNA
expression (Pace et al., 2002). It has yet to be determined whether the SCFADs used in
the study can produce the same synergistic effect on globin expression as seen when
combining sodium butyrate or alpha amino butyric acid with 5-azacytidine in chickens
and transgenic mice. SCFA impact other cellular functions in addition to acting as
inhibitors of histone deacetylation. For example, butyrate has been shown to arrest cell
growth in G1 phase, induce protein synthesis, and change cell morphology (Borenfreund
et al., 1980; Kruh, 1982; Rastl and Swetly, 1978). Induction of the y-globin gene has been
achieved in the absence of DNA methylation and HDAC inhibition. Specifically, yglobin mRNA can be induced via manipulation of cell signaling pathways including the
p38 MAP kinase pathway, the soluble guanylate cyclase-cGMP dependent kinase
pathway, and the 1-argininelnitric oxide/cGMP pathway (Bhanu et al., 2004; Haynes, Jr.

et al., 2004; Ikuta et al., 2001; Pace et al., 2003). In addition, induction of y-globin has
been seen with compounds that do not directly affect epigenetic modifications or cell
signaling pathways (Bianchi et al., 1999; Bianchi et al., 2001; Lampronti et al., 2003).
Taken together, the regulation of the globin locus involves cis elements, trans factors,
and epigenetic modifications. Understanding how all regulatory elements interact is
crucial to the establishment of proper treatment regimens for patients afflicted with
hemoglobinopathies.

Significance

Hemoglobinopathies are a group of pathologies characterized by a deficency in
the production of the hemoglobin molecule. Most hemoglobinopathies can be categorized
into one of two groups. The first group is able to produce structurally normal
hemoglobin, but erythropoiesis is ineffective (i.e., the thalassemias). The 0-thalassemias
are a group of disorders characterized by impaired P-chain synthesis leading to
ineffective erythropoiesis. Homozygous patients often die in their teens or early twenties
due to the severity of the anemia. The second group produces structurally abnormal
hemoglobin due to aberrant amino acid substitutions (i.e., sickle cell disease). Sickle cell
disease (SCD) affects 1 out of every 600 African Americans and is due to a single
mutation in the amino acid sequence (glutamic acid to valine at position 6 of the P-chain
subunit). The mutation allows the sickle hemoglobin to polymerize and distort the shape
of the erythrocyte. As a result, cells lose flexibility and are prone to block the

microvasculature leading to painful crises. The course of the disease varies from patient
to patient depending on various parameters. However, the life of a sickle cell patient is
often shortened and full of pain. Patients with hemoglobinopathies and a genetic mutation
leading to hereditary persistence of fetal hemoglobin often show less severe to no signs of
the disorder. In 0-thalassemia, the expression of the y-chain can compensate for loss of 0and &-chainsynthesis. The Cooperative Study of Sickle Cell Disease, a large multicenter
study of the history of SCD, showed an inverse correlation between levels of fetal
hemoglobin and painful crises and early death (Platt et al., 1991; Platt et al., 1994). Fetal
hemoglobin was also shown to have a sparing effect on polymerization of
deoxyhemoglobin S, the cause of membrane deformability in SCD (Poillon et a]., 1993).
In addition, the 0- and a-embryonic genes, E - and {-globin, have been shown to inhibit
the polymerization process in vitro and in vivo (He and Russell, 2002; He and Russell,
2004). Expression of both these genes was also able to reverse a mouse model of a- and
P-thalassemia (Russell and Liebhaber, 1998). The induction of silent globin genes is the
primary treatment option for patients with hemoglobinopathies. Many clinical trials are
currently ongoing in an effort to find the best compound(s) to treat these patients (Atweh
et al., 2003). However, the currently prescribed treatments are either highly toxic or
ineffective in a subset of patients. Therefore, dissecting the exact mechanism(s) of globin
gene silencing will lead to safer and more effective treatment options for patients.
Included in this are compounds that more specifically target the globin gene silencing
process and possibly gene specific therapy.

The impact of this study is not solely limited to the realm of hemoglobinopathies.
Epigenetic modifications have been implicated in many disease processes. Specifically,
abnormalities in DNA methylation are associated with mental retardation, disorders of
imprinting, and cancer. Expansion and methylation of a CGG repeat in the FMRl 5'
untranslated region leads to gene silencing in Fragile X syndrome (Oostra and
Willemsen, 2002). DNA methylation plays a crucial role in genomic imprinting.
Dysregulation of the imprinted genes is associated with Angelman syndrome, PraderWilli Syndrome, and Beckwith-Wiedemann Syndrome (Egger et al., 2004). DNA
methylation also plays a role in the development of many cancers. In fact, epigenetic
silencing has been recognized as a third pathway satisfying Knudson7shypothesis that
two hits are necessary for the silencing of tumor suppressor genes (Jones and Laird,
1999). For example, the gene encoding MLH1 is often methylated and silenced in
patients with sporadic colorectal cancers with microsatellite instability phenotype (Kane
et al., 1997). Thus, discerning the role of epigenetics in globin gene silencing may have a
direct impact on other disorders where epigentics play a critical role in pathogenesis.

CHAPTER 2: Generation and Analysis of Globin Gene Regulation in Transgenic
Knock-out BYACIMBD2-I- Mice

Introduction
Methylation of the 5' position of cytosine in the CpG dinucleotide in vertebrates
is associated with transcriptional repression. A group of proteins, the methyl-CpG
binding proteins (MCBP), specifically recognizes and binds to DNA sequences
containing methylated cytosines. Most of these proteins belong to a subgroup based on
the common features of a characteristic domain, the Methyl-CpG Binding Domain
(MBD), which is necessary and sufficient for binding of the proteins to methylated-DNA
(Nan et al., 1993). The MBD protein family consists of MeCP2, MBD1, MBD2, MBD3,
and MBD4. MBD2 and MeCP2 have been found to bind methylated-DNA as large multiprotein complexes (Feng and Zhang, 2001; Jones et al., 1998; Nan et al., 1998). MBD4
differs from the other MBD proteins in that its primary function is as a DNA repair
enzyme. DNA methylation mediated transcriptional repression is thought to be due to the
recruitment of MCBPs and repressive protein complexes to methylated DNA. These
complexes are thought to mediate transcriptional repression by recruiting histone
deacetylases and transcriptional repressor proteins to methylated-DNA (Chen et al., 2003;
Hutchins et al., 2002; Lin and Nelson, 2003; Magdinier and Wolffe, 2001; Sarraf and

Stancheva, 2004). MBD2 is part of the methyl-CpG binding protein complex 1 (MeCP1)
which contains Mi-2, MTA1, MTA2, MBD3, HDAC1, HDAC2, RbAp46, and RbAp48
(Feng and Zhang, 2001). Early studies suggested an interaction between MeCP2 and the
SIN3A transcriptional repression complex. However, recent evidence indicates this
interaction may not be stable (Klose and Bird, 2004). Brahma, a component of the
SWVSNF nucleosonie remodeling complex, does form a stable complex with MeCP2
(Harikrishnan et al., 2005). The Kaiso factor represents another type of methyl CpG
binding protein that contains a transcriptional repressor domain as well as a zinc finger
domain that confers sequence specificity, but lacks an MBD (Prokhortchouk et al., 2001).
The zinc fingers of Kaiso can bind methylated CGCGs or the Kaiso Binding Site
TCCTGCNA (Daniel et al., 2002).
Targeted deletions of methyl CpG binding proteins have yielded insight into the
functions of these proteins in vivo.Mice null for MBD1 have deficits in adult
neurogenesis and hippocampal function (Zhao et al., 2003). Mice lacking functional
MeCP2 display a phenotype similar to Rett Syndrome, a human neurodevelopmental
disorder leading to loss of voluntary movements (Guy et al., 2001). Loss of MBD2 has a
milder phenotype with the chief manifestation being decreased maternal nurturing of
pups (Hendrich et al., 2001). Loss of MBD2 specifically interferes with the regulation of
the IL-4 gene in mouse Thl and Th2 lymphocytes indicating that MBD2 can contribute
to the regulation of genes in a tissue specific manner (Hutchins et al., 2002). However, no
other genes have been reported to be primarily regulated by MBD2 in non-cancerous
cells. Unlike the embryonic lethal phenotype of DNA methyltransferase (DNMT) knock-

out mice, loss of MBDs is not catastrophic, indicating MBDs may compensate for each or
that only a small number of genes required for normal cell function are regulated by any
specific MBD (Li et al., 1992; Okano et al., 1999). Interestingly, Kaiso, a methyl-CpG
binding protein not in the family of MBD containing genes, has been shown to be
essential for Xenopus development (Ruzov et al., 2004).
The genes of the human P-globin locus are expressed sequentially during
development in the order they appear on chromosome 11: 5'

E-,

Gy-,*T-, and P-3'. The

individual genes have been shown to be regulated by a complex interplay between cis
elements, trans factors, conlpetition for an upstream enhancer, and epigenetics
(Stamatoyannopoulos and Grosveld, 2001). Despite a tremendous amount of progress in
this field, the exact mechanism(s) of globin gene silencing is still not understood. The
initial observation in vertebrates that DNA methylation is inversely related to gene
expression was noted in the globin locus (McGhee and Ginder, 1979). Furthermore, the
globin genes were the first group of genes for which the DNA methyltransferase
inhibitor, 5-azacytidine, was shown to activate silenced embryonic and fetal genes in vivo
in both animal models and in a therapeutic setting (Charache et al., 1983; DeSimone et
al., 1982; Ginder et al., 1984; Ley et al., 1982). Previously, we have shown a role for
DNA methylation and MBD2 in the developmental regulation of the chicken embryonic
p-globin gene (Bums et al., 1988; Ginder et al., 1984; Singal et al., 1997; Singal et al.,
2002). The p-globin gene becomes highly methylated at the same time the gene becomes
silent. Furthermore, the p-globin gene is enriched for MBD2 in adult erythrocytes when
the gene is silent, but not when it is actively transcribed. Finally, a protein complex

containing MBD2 purified from primary chicken erythrocytes binds to a methylated pglobin gene 5' sequence and differs in biochemical make-up from MeCPl (Kransdorf and
Ginder, 2004). These findings are evidence that MCBPs may form unique tissue
restricted complexes that are targeted to specific sets of genes. Taken together, this
evidence suggests MBD2 may be involved in the process of globin gene silencing by
DNA methylation.
To determine .the role of MBD2 in mammalian globin gene silencing, mice
containing the entire human globin locus as a yeast artificial chromosome (PYAC ) were
bred with mice containing a targeted deletion of MBD2. Adult PYACIMBD2-I- mice
inappropriately express the y-globin gene at a level commensurate to mice treated with 5azacytidine, while adult PYAC mice express the y-globin gene at much lower level. This
is, to our knowledge, the first evidence of a specific MCBP regulating y-globin
expression. In addition, loss of MBD2 delays the silencing of the y-globin gene during
embryonic development. Loss of MBD2 slightly decreases DNA methylation levels
around the y-globin pron~oter,and inhibiting DNA methylation does not greatly enhance
the expression of the y-globin gene, indicating the induction seen in knockout mice is not
largely dependent on DNA methylation or that the additional effect of 5-azacytidine is
mediated by a different MCBP.

Methods
Generation of PYACIMBD2-I- Mice

MBD2-I- mice (a generous gift from Dr. Adrian Bird) were mated with PYAC
mice (a generous gift from Dr. Karin Gaensler). The subsequent flACIMBD2+I- mice
were bred with MBD2-I- mice to generate PYACIMBD2-I- mice. To maintain the line,
PYACIMBD2-I- were bred with MBD2-I- mice. All progeny were screened for the
presence of the transgene and absence of MBD2 using PCR of DNA from tail snips.
Primers used to screen mice are located in Table 2. Two lines of PYAC mice were used
to generate transgenic knock-out mice, the A20.1 and A85.68 lines. Both contain a single
copy of the f l A C transgene in the C57 B116 background (A20.1) or the FVBIN
background (A85.68). The MBD2-I- mice are in the BALBIC background. Through
multiple rounds of breeding to establish and maintain lines, the final transgenic knock-out
mice were in a heterogeneous genetic background.

Generation of PYACIMeCP2-I- Mice
Female MeCP2+/- mice (Jackson Laboratories) were bred with A20.1 f l A C
transgenic mice. The MeCP2 gene is located on the X-chromosome, therefore only one
round of breeding was necessary to generate flACIMeCP2-Iy mice. All mice were
screened for the presence of the transgene and absence of MeCP2 using PCR from tail
snip DNA (Table 2).

Red Cell Lndices
Peripheral blood was extracted from the inferior vena cava of three non-anemic
mice of each genotype. The blood was collected in a citrate coated lavender top tube. The

blood was analyzed on a Coulter Hematology Analyzer (Beckman Coulter).
Reticulocytes were counted manually after staining with methylene blue for 15 minutes at
37" C. 1000 cells were counted per analysis.

Timed Matings
For MBD2 wild type embryos, PYAC males were bred with non-transgenic
females. For MBD2-I- embryos, mACIMBD2-I- males were bred with non-transgenic
MBD2-I- females. The presence of a vaginal plug was designated day 0.5. Fetal livers
were dissected from day 14.5 and 16.5 embryos.

Treatments
Mice were treated for two days with intraperitoneal injection of l-acetyl-2phenylhydrazine (10 mg/mL, Sigma) at a dose of 0.4 mgIl0g. On the third day, mice
were treated with 5-azacytidine (0.5 mg/mL, Sigma) at a dose of 2 mglkg for five days
via intraperitoneal injection.

RNA Isolation
RNA was extracted from fetal livers or peripheral blood using Trizol
(Invitrogen). Fetal livers were homogenized in 200 pL of Trizol in a 1.5 niL tube. The
volume was then increased to 1 mL with Trizol. Peripheral blood was added directly to I
mL of Trizol. 200 FL of CHC13 was added to the tube and shaken vigorously for 20
seconds and allowed to sit at room temperature for 3 minutes. The tube was spun at

Primer

Sequence

Beta 488 NC

GAGGGGAAAAGGTCTTCTACTTGG

Beta 161 BC

CCCTACGCTGACCTCATAAATGC

MBD2-17390-F

CCTCAGCTGGCAAGATACCT

MBD2-17507-R

GGGGGTCATTCCGGAGTCT

bGeo-3084-F

GGTCAGGTCATGGATGAGCAGA

bGeo-3286-R

CGCGGATCATCGGTCAGACGATT

MeCP2 Common

GGTAAAGACCCATGTGACCC

MeCP2 W O

TCCACCTAGCCTGCCTGTAC

MeCP2 W T

GGCTTGCCACATGACAA

Table 2:List of primers used to screen transgenic and knock-out PYAC0020mice.

12000 x G for 15 minutes at 4' C. The upper aqueous phase was collected and
precipitated with 83% volume of isopropanol at room temperature for 10 minutes
followed by centrifugation at 12000xg for 10 minutes at 4OC. The resulting RNA pellet
was washed with 70% ethanol/30% DEPC-treated water and air dried. The pellet was
resuspended in DEPC-water containing 1 pL of SuperRNasIN (Ambion) per 40 pL of
DEPC-water. Fetal liver RNA was further purified by LiCl precipitation. The RNA
concentration was determined using a UV spectrophotometer.

RNase Protection Assay
Single stranded, radiolabeled cRNA probes were synthesized using SP6
polymerase and ( x _ ~UTP
~ P (MP Biomedicals) with various templates. The mouse a globin probe was derived from a 309 bp fragment at the 3' end of the gene cloned into
pSP6 vector (Curtin et al., 1989). Probes for y-globin analysis were from a 1.7 kb
fragment of the Ay-globin gene protecting two bands (205, 144bp) when cut with EcoRI
or one band when cut with NcoI (1 88bp). The fragment was cloned into the pGEM-3zf(-)
plasmid (Promega). To discriminate between "y- and "yglobin mRNA, a probe identical
to one used previously was generated by PCR (Morley et al., 1991). The PCR product
was cloned into the pGEM-EZ plasmid (Promega). The forward primer contained a
HirzdIII site to make a linear template protecting a 21 5 bp fragment for Ay-globin mRNA
and a 135 bp fragment for Gy-globin gene. For the detection of y-globin, 500 ng RNA was
analyzed per RPA. For mouse a-globin analysis, 10 ng of RNA was used per analysis.
RNA was hybridized overnight at 42OC with 1 x 1 0 ~cpm of probe in 30 pL of

hybridization buffer containing 80% formamide. After hybridization, the y-globin and aglobin samples were combined for RNase digestion so both samples could be run on the
same gel. The samples were digested with RNase digestion buffer (300mM NaC1, 10mM
Tris-C1, pH 7.4, 5mM EDTA, pH 7.5) containing RNase A (Roche, 20 pg per sample)
and RNase T1 (150 U per sample) at 37°C for 30 minutes. The enzymes were inactivated
by treating with Proteinase K (60 pg per sample) and SDS (10 pL of 20% stock) at 37OC
for 30 minutes. The RNA was extracted with phenol and chloroform and ethanol
precipitated. The samples analyzed on a 6% denaturing polyacrylmide gel containing 7 M
urea. Band intensity was determined using a Phosphor-Imager (Molecular Dynamics).

RNA level was determined relative to the amount per copy of mouse cx-globin.

Bisulfite Conversion
Mice were treated with 1-acetyl-2-phenylhydrazine for two days and harvested on
the fifth or seventh day. Genomic DNA was isolated from spleens using .the Zymo
Research genomic isolation kit (Zynio Research). The DNA was bisulfite converted using
the Zynio Research EZ methylation kit. Genomic DNA (- 1 pg) was diluted to 45 pL in
water and heated at 95" C for 5 minutes. The DNA was further denatured by adding 5 pL
M-dilution buffer and incubated at 37" C for 15 minutes followed by the addition of 100
pL of bisulfite conversion solution. The samples were incubated at 50" C overnight. The
bisulfite converted DNA was purified on a spin-column and eluted in water. Bisulfite
converted DNA was amplified using nested PCR with primers for either Gy-or *yglobin
promoter region. Primers were designed so that the last nucleotide in the primer was a

thyrnidine in the bisulfite converted and cytosine in normal genomic DNA to prevent the
amplification of non-converted DNA. PCR products were cloned, screened, and
sequenced. Primers used for bisulfite specific PCR are listed in Table 3.

Chromatin Immunoprecipitation
Mice were treated for two days with 1-acetyl-2-phenylhydrazine. On the fifth
day, spleens were harvested and gently brushed into single cell suspension in ice cold
W M I containing 2% FBS, 5 n1M Butyrate, PMSF, aprotinin, leupeptin, and pepstatin.
Butyrate and protease inhibitors were included in all steps until TE washes. Cells were
then passed through a 70 pM nylon filter to remove debris. Cells were spun and washed
with ice cold PBS containing 2% FBS (PBSIFBS). Cells were then resuspended in room
temperature PBSEBS. Formaldehyde was added drop-wise to a final concentration of
0.4% and cells crosslinked for 10 minutes at room temperature. The reaction was
terminated by adding glycine to 0.125M and incubating at room temperature for 5
minutes. Cells were washed twice with PBSEBS. Cells were resuspended in SDSILysis
buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) at a concentration of 25-30 mg
spleen1200 pL and incubated on ice for 10 minutes. Chromatin (-700 pL with 200 pL
glass beads) was sonicated by six 20 second pulses at 27.5% on a sonicator fitted with a 4
mm tip to achieve 200-1 000bp (mean 600bp) DNA. Cellular debris was removed by
centrifugation at 12000 rpm for 10 minutes at 4OC. The sonicated chromatin was diluted
ten-fold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7
mM Tris-HC1, pH 8.1, 167 mM NaC1). Diluted chromatin was pre-cleared with 80 pL

Primer

Sequence

5-A-START- 1

GGAGTTATAGATAAGAAGGTC

5-G-START-2

GGAGTTATAGATAAGAAGGTG

G-START-2

GGTATTTTTTATGGTGGGAGAAGA

A-START-2

GGTATTTTTTATGATGGGAGAAGG

3-END-2

CCAAAACTATCAAAAAACCTCTAA

3-END-1

CCTTCTTACCATATACCTTAACTTTTA

Table 3: Primers used for bisulfite specific PCR of the y-globin promoter region.

protein A agarose/salmon sperm DNA slurry (Upstate Biotechnology) per 2 mL diluted
chromatin by rotating at 4°C for 30 minutes. The diluted chromatin was spun at 2000 rpm
at 4°C for 2 minutes and aliquoted into 2 mL (25 mg spleen) samples for
immunoprecipiation with anti-acetyl H3 (Upstate Biotechnology), anti-acetyl H4
(Upstate Biotechnology), anti-Pol I1 (Santa Cruz), rabbit pre-immune serum (Santa Cruz
Biotechnology), and anti-Trimethyl H3 K4 (Abcam and Upstate), and normal rabbit IgG
(Upstate Biotechnology) and incubated overnight with rotation at 4°C. A 500 pL aliquot
was stored at -20°C for use as the input sample. Samples were mixed with 60 pL protein
A agarose/salmon sperm and rotated for an additional 2 hours at 4" C. Samples were spun
at 2000 rpm for 2 minutes at 4°C. The supernatant was removed and the beads were
washed with 1 mL low salt wash (0.1% SDS, 1% Triton X-100,2 mM EDTA, 20 mM
Tris-HC1, pH 8.1, 150 mM NaC1) by rotating at 4°C for 5 minutes. The beads were spun
down at 2000 rpm for 2 minutes and washed again with 1 mL high salt wash (0.1% SDS,
1% Triton X-100,2 mM EDTA, 20 mM Tris-HC1, pH 8.1, 500 mM NaCl). The washing
process was repeated three more times, once with a LiCl buffer (0.25 M LiC1, 1%
IGEPAL-CA630, 1% deoxycholic acid, 1 mM EDTA, 1OmM Tris-HC1, pH 8.1) and
twice with TE (10 mM Tris-HC1, 1 mM EDTA, pH 8.0). After the final wash, the
immune complexes were eluted by adding 250 pL elution buffer (0.1 M NaHC03, 1%
SDS), vortexing briefly, and rotating at room temperature for 20 minutes. The beads were
then spun down at 2000 rpm for 2 minutes at room temperature and the supernatant
collected. The beads were then eluted a second time with 250 pL of elution buffer. The
formaldehyde crosslinks were reversed by adding 50 pL 3 M NaCl and 1 pL RNase A

(20 mg/mL) and heating at 65" C overnight. Protein was digested by adding 20 pL Tris
pH 6.5, 10 pL 0.5 M EDTA, and 1 pL Proteinase K (20 mg/mL) and incubating at 45" C
for 2 hours. The samples were then extracted once with phenol and CHC13 and once with
chloroform followed by ethanol precipitation. DNA pellets were dissolved in water and
quantitated using the PicoGreen assay (Molecular Probes, Carlsbad, California). The
amount of globin gene present in the immunoprecipitated samples was determined by real
time PCR using ~ a ~ ~ probes
a n (Perkin-Elmer
~ "
Applied Biosystems) on an ABI 7500
or 7900 HT. The levels of enrichment were normalized to the non-specific mouse
amylase gene to account for variations during immunoprecipitations. Primer and probe
sequences used for real-time PCR analysis are located in Table 4. ChIP analysis
performed on fetal livers was identical to the above procedure with the following
exceptions. Frozen fetal livers were thawed and gently pipetted into a suspension. Half a
fetal liver was used per immunoprecipitation.

RT-Real-Time PCR
RNA (3.7 pg) was first treated with DNase I using the Turbo DNA-Free
(Ambion). DNase-treated RNA (1 pg) was reverse transcribed using Script (Bio-Rad)
cycling at 25" C for 5 minutes, 42" C for 30 minutes, and 85" C for 5 minutes. cDNA was
analyzed using y-globin primers (25 ng) and mouse a-globin primers (5 ng) and SYBR
green chemistry on an ABI 7500 or 7900HT Sequence Detection System. Levels of yglobin expression were normalized to endogenous mouse a-globin expression. Primer
sequence used for real-time PCR analysis are found in Table 5. Additional analysis was

Primer

Sequence

GammaIn2-F

GGAGATGTTTCAGCACTGTTGCCT

GammaIn2-R

1

AGCCCAGTTAGTCCTCTGCAGTTT

Amylase-F

AGTTCGTTCTGCTGCTTTCCCTCA

Amylase-Probe

tetTTCTGCTGGGCTCAATATGACCCACAtamra

Amylase-R
hBetaExn#2-F

I TTCCTTGGCAATATCAACCCAGCG

1

TACCCTTGGACCCAGAGGTTCTTT

TAAAGGCACCGAGCACTTTCTTGC

hBetaExn#2-R
I

Table 4: List of primers used for real-time PCR analysis of ChIP assay DNA in Chapter
2.

Primer

Sequence

MouseBetaHl-F

AGGCAGCTATCACAAGCATCTG

MouseBetaH1Probe

6famGAAACTCTGGGAAGGCTCCTGATTGTTTACCtamra

Mouse Beta HI-R

AACTTGTCAAAGAATCTCTGAGTCCAT

Mouse Ey-F

CAAGCTACATGTGGATCCTGAGAA

Mouse Ey-Probe

6famTCAAACTCTTGGGTAATGTGCTGGTGATTGtamra

Human E-globin-F

GCCTTTGCTAAGCTGAGTGAG

Human E-globin-Probe 6famTCAAGCTCCTGGGTAACGTGATGGTGAtamra
Human €-globin-R

TTGCCAAAGTGAGTAGCCAGAA

Human y-globin-F

GTGGAAGATGCTGGAGGAGAAA

Human y-globinProbe

6famAGGCTCCTGGTTGTCTACCCATGGACCtamra

Human y-globin-~

TGCCATGTGCCTTGACTTTG

Mouse GlycophorinA-F GCCGAATGACAAAGAAAAGTTCA
Mouse GlycophorinA-P 6famTTGACATCCAATCTCCTGAGGGTGGTGAtamra
Mouse GlycophorinA-R TCAATAGAACTCAAAGGCACACTGT

I

Mouse zeta-F

GCGAGCTGCATGCCTACAT

Mouse zeta-Probe

6famTGGATCCGGTCAACTTCAAGCTCCTGTtamra

Mouse zeta-R
Malpha-2F

I Table
I

1

I
AATATGGAGCTGAAGCCCTGG
ACATCAAAGTGAGGGAAGTAGGTCT

Ma1pha-2
5:Primers used for real-timePCR expression analysis in Chapter 2.
I

I
I

performed using ~ a ~ m probes
a n ~
for ~detections of glycophorin A, human c-, cy-, phl-,
and {-globin transcripts (Table 5).

Results

Two lines of mice containing the entire human 6-globin locus as a yeast artificial
chromosome (PYAC) were used in these studies, A20.1 and A85.68 (Figure 4) (Porcu et
al., 1997). PYAClMBD2-I- mice were generated by breeding PYAC mice with MBD2-Imice and breeding the subsequent transgenic hemizygotes with MBD2-1- mice.
PYACMBD2-I- mice were treated with 1-acetyl-2-phenylhydrazine to induce hemolytic
anemia for the purpose of increasing the number of reticulocytes for RNA analysis.
Peripheral blood was collected on the third day after treatment. For 5-azacytidine
treatment, PYACIMBD2+1+ mice were treated for 2 days with 1-acetyl-2phenylhydrazine followed by 5 days of intraperitoneal5-azacytidine treatment. Peripheral
blood was collected the day after the final treatment. Globin gene expression was
analyzed using the RNase protection assay. As seen in Figure 5, y-globin mRNA was
barely detectable by this assay in adult PYAC/MBD2+/+ mice and PYAC/MBD2+/mice. However, PYAClMBD2-I- and PYAC/MBD2+/+ mice treated with 5-azacytidine
express the silenced y-globin gene at similar increased levels. Both A20.1 PYACMBD2I- and PYAC mice treated with 5-azacytidine express the y-globin gene at -2% of mouse
alpha globin (Figure 6). A slightly higher level of expression is seen in MBD2 null mice
derived from A85.68 PYAC transgenic mice. In addition, this effect is seen in MBD2-I-

LCR

3' HSS

Figure 4: Constructs used to generate PYAC transgenic mice. The top line is a
representation of the human P-globin locus. The A20.1 constructs contains -150kb of
sequence while .the A85.68 contains >200kb of sequence. The vertical gray bars indicate
the position of the genes in the locus; Black arrows indicate DNase I hypersensitive sites.
Horizontal gray bars indicate YAC arms. LCR = locus control region. HSS = DNase I
hypersensitive site.

Figure 5: RPA analysis of y-globin expression in wild type and MBD2 null PYAC
transgenic mice. Both lines of f l A C transgenic mice express nominal levels of 7-globin
mFWA in the MBD2+/+ and MBD2+/- background. Treatment with 5-azacytidine or loss
of functional MBD2 leads to a pronounced increased in y-globin expression in both lines.
Treatment of a 20.1 PYACIMBD2-I- mouse with 5-azacytidine leads to slight additive
boost in yglobin expression. The endogenous mouse a-globin gene was used as a loading
control and was hybridized using 50-fold less RNA. The samples were hybridized
separately and combined for RNase digestion.

MBD2-I-

MBDZ+I+
and +I-

MBD2-1-

Figure 6: Quantitative analysis of y-globin expression in wild type and MBD2 null PYAC
transgenic mice. Bands from RPA were quantitated using a phosphor-imager. The level of
expression of the y-globin gene was calculated relative to the per copy expression of the
mouse a-globin gene. Shown above are the results from the A20.1 line of PYAC transgenic
mice and the A85.68 line of PYAC transgenic mice. Either treatment with 5-azacytidine or
loss of MBD2 results in expression of the y-globin gene to -2% of mouse a-globin
expression. The results shown are the average of three RPAs from at least two different
mice. For the A85.68 mice, the MBD2+/+ and +/- is the average value from one mouse of
each genotype.

mice not made anemic with 1-acetyl-2-phenylhydrazine (Figure 7). No endogenous
mouse embryonic globin transcripts were detectable by RNase protection assay (Figure
8). Very low levels of endogenous mouse globin genes are detected by real-time PCR,
however, they show large error bars indicating inconsistent low level expression that does
not differ between genotype or treatment (Figure 8). The effect on human €-globin
expression is discussed in Chapter 3. However,,we have observed that a human epsilon
transgene containing a full LCR and 4 kb of downstream flanking sequence but no y- or
0-globin gene is activated in the MBD2-I- background. Thus, MBD2 is necessary for
maintaining near complete y-globin silencing in adult mice and loss of MBD2 resuIts in
markedly increased y-globin expression but not mouse or human embryonic 0-type
globin genes. This is likely due to the ability of the fetal gene but not the embryonic'
genes to partially compete with adult @-globingene for the LCR. In addition, the level of
induction after treatment with 5-azacytidine is additive, not synergistic, indicating MBD2
and 5-azacytidine likely work through the same mechanism via DNA methylation.
Alternatively, the additive increase in y-globin mRNA may be due to the cytoxic effect of
the compound or compensation by a different methyl CpG binding protein. The
percentage of 'y- vs. Ay-globinwas determined using an RNase protection assay probe
that discriminates between the two genes (Morley et al., 1991). The % Ay-globin mRNA
was 60% for PYAClMBD2-I- mice and 70% for PYAClMBD2-tl-t mice treated with 5azacytidine (Figure 9). These values are very similar to the level seen in adult human Fcells and opposite to the "y- to Gy-globinratio in K562, cells suggesting that the y-globin
mFWA is from cells with a definitive program rather than due to a reactivation of

Figure 7: Real-time PCR was performed on peripheral blood taken from non-anemic
MBD2+/+ and MBD2-1- A20.1 PYAC transgenic mice. The relative level of y-globin
expression was determined relative to glycophorin A. The results indicate that the yglobin gene is expressed even when MBD2-1- mice are not treated with 1-acetyl-2phenyl-hydrazine.

B h l /GIyA
ey/GlyA

Figure 8: Treatment with 5-azacytidine treatment or loss of MBD2 does not induce
expression of any endogenous embryonic globin gene. The top panel shows an RPA of
cy- and r-globin expression in MBD2+/+ and MBD2-1- peripheral blood. W A analysis
was unable to detect expression of either globin gene. The bottom panel shows real-time
PCR analysis of endogenous globin gene expression in MBD2+/+ mice, MBD2+/+ mice
treated with 5-azacytidine, MBD2-1- mice, and MBD2-1- mice treated with 5-azacytidine.
Low levels of all transcripts are detectable, but no significant increases are observed after
5-azacytidine treatment or after loss of MBD2. In addition, the level of expression is
>1000-fold less than that seen in the 10.5 dpc yolk sac.

Figure 9: Ratio of Ay-globinto total y-globin expression in P A C transgenic mice treated
with 5-azacytidine and PYAC mice null for MBD2. The RPA probe used in the top panel
discriminates between the
and Gy-globingenes. The ratio of the two genes was
determined by phosphor-image analysis and indicates that the level of expression of the
A
y-globin gene is slightly higher in both 5-azacytidine treated mice and MBD2 null mice.
K562 cells show a preference for 'yglobin gene expression.

primitive erythropoiesis. Red cell indices were compared between non-anemic wild-type
and knock-out mice. The results show no significant difference except for slight
microcytosis in MBD2 null mice (Table 6).
Adult erythroid cells from mice lacking MBD2 inappropriately express the yglobin gene. We next wanted to determine the impact of MBD2 on globin gene
expression during development. Timed matings were performed and embryos harvested
on 14.5 and 16.5 days post coitus (dpc). At 14.5 dpc, embryos lacking MBD2 expressed
2-fold more y-globin than wild type embryos (Figure 10). This difference increased to
3 -5-fold in 16.5dpc fetal livers (Figure 10). The effect seen in adult knock-out mice
appears to be at least partly due to an inability to fully silence the y-globin gene during
the switch to definitive erythropoiesis. Therefore, the effect is specific for the y-globin
and not the embryonic globin genes in the context of PYAC transgenic mice.
Lack of MBD2 results in expression of the y-globin gene in adult PYAC
transgenic mice. MCBPs bind to methylated DNA and recruit factors that lead to
transcriptional repression. In addition, MBD2 has been shown to colocalize with DNA
methyl transferase 1 (DNMT1) (Tatematsu et al., 2000). We therefore postulated that if
MBD2 binds at or near the y-globin gene promoter the effect seen in adult PYACIMBD2I- mice may be accompanied by a loss of DNA methylation around the y-globin
promoter. Bisulfite sequencing was performed to detem~inethe methylation status in
,8YACIMBD2+I+ mice, PYACIMBD2-tI-t mice treated with 5-azacytidine, and
PYACIMBD2-I- mice. A 70bp region containing four CpGs was analyzed around the y-

0

14.5 dpc

46.5 dpc

Figure 10: Expression of the y-globin gene during development in MBD2+/+ and MBD2I- PYAC transgenic mice. The level of expression of the y-globin gene was determined
during development in MBD2+/+ and MBD2-1- PYAC transgenic mice by RPA. During
development, loss of MBD2 results in increased expression of the y-globin gene in 14.5
and 16.5 dpc fetal liver erythroid cells.

RBC
MBD2+/+ 7.6h1.1

Hb

Hct

13.2*1.2

37.22r5.1 49.32r1.5

MCV

MCH

HCHC

Retic

17.52r0.9 35.8h1.8 6.22r0.9
I

MBD2-1-

6.72r1.6

11.7h2.7 30.32r8.1 44.6*0.3

17.2h0.4 38.6h1.2

5.9h1.5

P-Value

0.42

0.41

0.64

0.73

0.28

0.01

0.08

Table 6: Red blood cell indices were determined on three mice of each genotype. Pvalues were calculated by student t-test.

globin promoter. As shown in Figure 11, wild type adult erythroblasts show a high level
of methylation (75-100%) at each CpG tested in the y-globin gene. Furthermore, no
individual clone (represented as a row in Figure 8) was either completely or 175%
unmethylated indicating all cells are highly methylated around the y-globin promoter.
Treatment with 5-azacytidine led to a decrease in methylation at all sites (40-60%
methylated) with 4 clones having no methylation at any site tested. This result is similar
to results seen in MEL cells containing human chromosome 11 and primary erythroid
cells of patients treated with 5-azacytidine (Humphries et al., 1985; Ley et al., 1984).
Most MBD2-I- clones show an intermediate level of DNA methylation at each site (6090% methylated). In addition 1 clone is fully demethylated while another is 75%
demethylated. DNA methylation levels are only modestly decreased in the absence of
MBD2 compared animals treated with 5-azacytidine. This may be the result of increased
transcription of the gene preventing DNA methylation by DNMT rather than MBD2
recruiting DNMT activity to the y-globin promoter. Nevertheless, y-globin mRNA levels
can be increased in the absence of significant loss of DNA methylation around the
promoter and proximal transcribed regions. This suggests 5-azacytidine and MBD2 exert
their effect directly at the y-globin promoter region.
To determine whether loss of MBD2 alters post-translational histone modification
around the y-globin gene, chromatin immunoprecipitation ( C h P ) assays were performed.
Both PYACIMBD2+I+ and PYACIMBD2-I- mice were treated with l-acetyl-2phenylhydrazine to promote conversion of the spleen to a primarily erythroid organ

Wild Type pYAC

Wild Type PYAC + aza

Figure 11: Bisulfite analysis of MBD2+/+ and MBD2-1- D A C transgenic mice.
Genomic DNA from the spleens of anemic mice was treated with bisulfite. The yglobin gene promoter region was amplified by PCR, cloned, and sequenced. The
numbers above each figure indicate the position of CpG relative to the transcription
start site. The horizontal row indicates one sequenced clone with white bars indicating
an umethylated CpG, a black bar indicating a methylated CpG, and a gray bar
indicated an undetermined CpG.

(Spivak et al., 1973). Splenic erythroblasts were used for chromatin immunoprecipitatioi~
with antibodies directed against acetylated histone H3 (AcH3), acetylated histone H4
(AcH4) and trimethylated lysine 4 of histone H3 (TriMeK4), all of which are associated
with active transcription. Given that the level of y-globin mRNA is -2% of mouse aglobin mRNA in 0YACIMBD2-I- mice, we postulated that any effect on histone
modifications might be too small to determine. For this reason, the amount of enrichment
was normalized to the level seen in the inactive endogenous amylase gene control.
Immunoprecipitations were performed on two mice of each genotype. Shown in Figure
12 is the average gamma globin to amylase gene ratio for wild type and knockout mice.
The y-globin promoter region shows enrichment for AcH4, Pol 11, and TriMeK4 in
knock-out mice and no enrichment for these modifications in wild-type mice.
Additionally there is little change in the level of AcH3 in either genotype. Additionally,
the 5' region of the y-globin gene coding region is enriched -4-fold over baseline for
TriMeK4 in MBD2-1- mice while MBD2+/+ mice show baseline levels. Similar levels of
enrichment are seen when normalizing the gamma globin value to the active human 0globin gene. The level of enrichment at the highly expressed 0-globin gene is > 20-fold
higher than enrichment levels at the y-globin gene in MBD2 null mice (Figure 13). A
similar relationship between level of mRNA expression and active histone modification
enrichment is seen in mice containing a mutant human PYAC transgene that expresses
the human 0-globin gene at 3% of the normal transgene (Fang et al., 2005). The
enrichment of TriMeK4 in MBD2-I- mice may be due to the recruitment of histone
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Figure 12: Analysis of post-translational histone modifications at the y-globin gene
promoter and coding regions in wild type and MBD2 null PYAC transgenic mice. ChIP
assays were performed on splenocytes from anemic mice using antibodies against
TriMeK4, AcH3, AcH4, and Pol 11. Enrichment was determined relative to the inactive
amylase gene by real-time PCR. Non-specific background was accounted for by dividing
each value by the IgG ratio. Small horizontal black bars below the map of the human 0globin locus indicate the positions of PCR amplification.
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Figure 13: Analysis of post-translational histone modifications at .the P-globin gene in
wild type and MBD2 null PYAC transgenic mice. ChIP assays were performed on
splenocytes from anemic mice using antibodies against TriMeK4, AcH3, AcH4, and Pol
11. Enrichment was determined relative to the inactive amylase gene by real-time PCR.
The level of enrichment at the P-globin gene is >20-fold higher than at the y-globin gene.

methyltransferases to the y-globin gene by RNA polymerase I1 in the absence of MBD2
(Ng et al., 2003). As shown in Figure 6 and 10, the y-globin gene is expressed -10-fold
higher in the wild-type 14.5 dpc fetal liver than in adult MBD2 null erythroid cells. As
seen in Figure 14, the level of
enrichment for TriMeK4 is -10-fold higher as well. This data indicates that the level of
transcription is proportional to TriMeK4 enrichment and that the increase in y-globin
mRNA is due to increased transcription of the gene. In addition, there is no significant
difference between the level of AcH3 enrichment in wild-type versus MBD2 knock-out
mice at the y-globin gene (Figure 12). Once again, the level of enrichment of this
modification is much higher at the 0-globin gene (Figure 13). Loss of MBD2 leads to an
increase in TriMeK4, AcH4, and Pol I1 levels at the y-globin gene promoter and
increased TriMeK4 at the coding region but does not induce a similar increase in AcH3
levels.
Treatment of PYAC/MBD2+/+ mice with 5-azacytidine leads to a 10-15 fold
induction of the y-globin gene versus mice treated with 1-acetyl-2-phenylhydrazineonly
(Figure 12) which is similar to the level of activation seen in PYACIMBD2-1- mice and in
a different PYAC line treated with 5-azacytidine (Pace et al., 1994). To determine
whether 5-azacytidine and MBD2 both induce y-globin mRNA via the same mechanism
through DNA methylation, PYAClMBD2-1- mice were treated with 5-azacytidine. Blood
was collected prior to 5-azacytidine treatment and again five days after treatment and
analyzed by both RNase protection assay and quantitative real-time PCR (Figures 5 and
15, respectively). 5-azacytidine only induces the y-globin by 2.5-fold (25-fold over wild-
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Figure 14: ChIP assay was performed on 14.5 dpc wild-type PYAC fetal livers.
Chromatin was immunoprecipitated with anti-TriMeK4. The data is graphed relative to
enrichments levels seen in adult MBD2+/+ and MBD2-1- PYAC transgenic mice.

Figure 15: Analysis of 5-azacytidine mediated induction of the y-globin gene in
MBD2+/+ and MBD2-1- PYAC transgenic mice. Induction of the y-globin gene by 5azacytidne was determined relative to pre-treatment expression levels by real-time PCR.
Treatment with 5-azacytinde results in a >lo-fold induction in MBD2+/+ mice while
only a 2.5-fold induction is seen in MBD2-1- mice.

type) in MBD2-I- mice. The lack of a synergistic effect (>1000-fold over wild-type) of
MBD2 deficiency upon 5-azacytidine treatment strongly suggests that both are largely
working through the same pathway, which is mediated by DNA methylation. This
induction, while present, is sub-additive. However, the 2.5-fold induction may be due to
the cytoxic effect of the drug or compensation by another methyl CpG binding protein.
Furthermore, the activation of multiple pathways by 5-azacytidine is a possibility that
cannot be ruled out. These alternate pathways may be the cause of the sub-additive
induction.
To determine the specificity of the MBD2 mediated y-globin gene repression,
transgenic knock-out mice were made for a different MCBP, MeCP2. MeCP2 knock-out
mice have a more severe phenotype than MBD2 knock-out mice characterized by
uncoordinated gait, hind-limb collapsing, breathing irregularities, rapid weight loss, and
death by day 54 (Guy et al., 2001). These symptoms are similar to the human
neurological disorder Rett Syndrome, a disorder associated with MeCP2 loss or mutation.
Transgenic knock-outs can be generated in one round of breeding by mating a male
transgenic mouse with a hemizygous female. Multiple transgenic hemizygous females
were obtained, however only one transgenic knock-out mouse was generated. Transgenic
mice hemizygous for MeCP2 were made anemic and peripheral blood analyzed by RNase
.

protection assay. As shown in Figure 16, these adult mice do not express the human yglobin gene. Given that MeCP2 is X-linked, half of the blood cells should be null for
MeCP2. These results indicate that loss of MeCP2 is not sufficient to induce expression
of the y-globin gene. However, these results do not take into account the fact that other

Figure 16: Expression of globin genes in MeCP2yI- and MeCP2+/- PYAC transgenic
mice. The top panel shows an RPA for y-globin expression in MeCP2yI- and MeCP2+/transgenic mice. The bottom panel shows a real-time PCR analysis of expression of
globin genes in MeCP2yI- and MeCP2+/- @YAC transgenic mice. The level of expression
of the ~y globin gene is >1000-fold less than 10.5 dpc yolk sac expression levels.

factors expressed from other cells (ie cytokines) may be responsible for the induction of
the y-globin gene in MBD2 null mice. One mouse transgenic for the PYAC and null for
MeCP2 was generated. Peripheral blood was collected from this mouse without l-acetyl2-phenylhydrazine treatment due to the frail condition of the mouse. RNA from
peripheral blood was analyzed by RNase protection assay and real-time PCR. No yglobin RNA is expressed in this mouse (Figure 16). These results indicate that the effect
seen due to loss of MBD2 is specific, because loss of MeCP2 does not generate the same
phenotype.

Discussion

MBD2 is needed for complete suppression of the y-globin gene in PYAC
transgenic mice. Loss of the protein leads to a level of expression from a single copy of
the y-globin gene commensurate with PYAC mice treated with 5-azacytidine, -2% of the
endogenous mouse a-globin RNA per gene copy. In addition, developmental silencing of
the transgene is delayed in the absence of MBD2 as these mice express the y-globin gene
at higher levels in 14.5 and 16.5dpc fetal livers. DNA methylation levels are modestly
reduced while TriMeK4 levels are modestly increased around the y-globin gene in
PYACIMBD2-I- mice. Treatment of PYACIMBD2-I- mice with 5-azacytidine leads to
only a 2.5 fold induction of y-globin mRNA relative to PYAC mice treated with 5azacytidine.
The phenotype seen in MBD2 null PYAC transgenic mice appears to be due to
increased transcription. The level of enrichment of TriMeK4 is proportional to

transcriptional activity. As shown, there is an increase in TriMeK4 enrichment around the
y-globin gene in MBD2 null transgenic mice. Thus, it seems unlikely that MBD2 loss
leads to a stabilization of the y-globin mRNA or another non-transcriptional mechanism.
Cytotoxic compounds such as 5-azacytidine, hydroxyurea, and araC have been proposed
to increase fetal hemoglobin by inducing stress erythropoiesis (Stamatoyannopoulos,
2005). In stress erythropoiesis, early differentiating erythroid cells that express the yglobin gene are accelerated through the differentiation pathway before they can fully
silence the y-globin gene. Cytotoxic drugs result in increased erythropoiesis leading to
increased production of y-globin mRNA. Thus, we investigated whether MBD2 mediates
a stress erythropoiesis effect to induce y-globin mRNA expression. However, the red cell
indices, including reticulocyte count, are not different between the two genotypes.
Additionally, 1-acetyl-2-phenylhydrazine induced hemolytic anemia fails to increase yglobin mRNA levels in MBD2-I- mice. It therefore seems unlikely that MBD2 is
mediating a stress erythropoiesis effect to increase y-globin expression. However, it does
not eliminate the possibility that MBD2 is somehow altering erythroid differentiation in a
way that results in increased y-globin expression. In addition, the effect is very specific as
loss of MeCP2 does not create the same phenotype nor are any endogenous mouse globin
genes appreciably up-regulated in the absence of MBD2. Thus, it appears MBD2 is
mediating a specific transcriptional up-regulation of the y-globin gene.
Treatment of MBD2-I- mice with 5-azacytidine does not produce a synergistic
increase in y-globin expression. However, there is a sub-additive increase in y-globin
mRNA levels. There are four possible reasons to account for this effect. First, loss of

MBD2 and 5-azacytidine are working along the same pathway via DNA methylation to
repress y-globin transcription in adult m A C transgenic mice. Given this, treatment with
5-azacytidine in the MBD2 null background should not cause a further increase if both
are working via the mechanism. This idea is supported by the similar level of y-globin
mRNA after treatment with 5-azacytidine or in the absence of MBD2. Second, cytotoxic
drugs such as hydroxyurea and AraC have been shown to increase y-globin mRNA levels
in both huniaiis and baboons (Staniatoyannopoulos, 2005). Neither of these compounds
affects DNA methylation, but they are hypothesized to exert their effect by stimulating
stress erythropoiesis. The 2.5-fold induction seen may be the result of stress
erythropoiesis due to the cytotoxic nature of 5-azacytidine. Third, drug treatment can lead
to the activation or inactivation of many pathways. Treatment of 5-azacflidine in the
MBD2 null background may be impacting a pathway outside of DNA methylation to
create the 2.5-fold increase. Fourth, another MCBP may compensate for MBD2 loss. The
loss of DNA methylation via 5-azacytidine treatment alleviates its contribution to yglobin repression and creates a 2.5-fold induction in expression. However, most of the
known MCBPs can be eliminated as contributors. MeCP2 loss appeared to have no effect
of y-globin mRNA levels. Kaiso binds to a specific site not found in .the y-globin gene.
MBD3 does not bind to methylated DNA and MBD4 is a repair enzyme. As a result,
MBDl is the only other known MCBP that could contribute to y-globin gene repression.
Most MCBPs are thought to inhibit transcription by binding to promoters and
recruiting transcriptional repression complexes. We have shown here only minor changes
in DNA methylation status and post translational histone modifications around the y-

globin gene in PYACIMBD2-I- mice. This is not completely surprising as the y-globin
promoter does not possess a CpG island, a region of 200bp or more that have a CpG:GpC
ratio of 0.6 (Antequera and Bird, 1993; Cross and Bird, 1995). In addition, there are no
significant changes in global DNA methylation levels in MBD2-I- mice (Hendrich et al.,
200 1). Tl~us,MBD2 is not recruiting DNMT-activity to the y-globin gene. The modest
decrease in DNA methylation levels seen in at the y-globin promoter region is likely due
to increased transcription of the gene preventing DNMT-activity. While MBD2 has been
shown to bind to as few as 2 CpG in vitro, this has not been shown in vivo (Kransdorf and
Cinder, 2004). Thus it appears unlikely MBD2 binds directly to the y-globin promoter to
mediate transcriptional repression of the y-globin gene for three reasons. First, the low
CpG density is not an ideal binding site for MBD2. Second, MCBPs mediate their
repressive effects through recruitment of transcriptional repression complexes that
include HDACs. If MBD2 were recruited to the y-globin gene there should be an increase
in both AcH3 and AcH4 in its absence. Instead, there is only enrichment for AcH4 at the
promoter with no increase in AcH3 and no increase in AcH3 or AcH4 within the coding
region. Third, work in cell hybrids shows the y-promoter region is unmethylated in the
absence of transcription (Enver et al., 1988). The data here shows that y-globin
expression stays high during development in the absence of MBD2, indicating MBD2 is
necessary for silencing during development. If the promoter is still unmethylated at this
time, MBD2 cannot be mediating its effect directly at the gene. Loss of MBD2 or 5azacytidine treatment leads to increased expression of the y-globin gene in PYAC
transgenic mice. Both appear to be working via the same mechanism that likely does not

involve the y-globin promoter. MBD2 may be mediating its effect at a different location
in the locus. The NuRD complex has recently been shown to be recruited to HS2 of the
LCR in K562 cells (Mahajan et al., 2005). However, MBD2 was not shown to bind there,
but MBD2 may be mediating its effect through a CpG dense region in the locus. The 6globin locus does not possess a true CpG island, but it does contain pockets of increased
CpG density. MBD2 binding at these sites may contribute to y-globin gene silencing. In
addition, MBD2 may be regulating a gene in trans that when expressed increases yglobin gene expression.
Many compounds currently available to treat patients with hemoglobinopathies
are toxic and, in addition, the response to the agents is variable. Here we show that loss of
MBD2 leads to expression of the normally silent y-globin gene in adult PYAC transgenic
mice. Given the mild phenotype of MBD2 null mice, MBD2 may represent an attractive
potential target for the treatment of /3-thalassemia or sickle cell anemia conditions in
which increased y-globin gene expression has an ameliorating effect.

Chapter 3: The Role of DNA Methylation and MBD2 on Human c-globin
Regulation

Introduction:
The genes of the human P-globin locus are located on chromosome 11 in the order
of their expression during development: 5'

6 , y,

and /3 3'. During development, two

switches occurs whereby the 5' globin gene (c or y) becomes silent and the gene directly

3' becomes transcriptionally active. The exact mechanism of this process is not yet fully
understood, however it has been show to involve many interactions between cis elements,
erythroid specific trans factors, ubiquitous trans factors, and epigenetics. Transgenic
mice with the human @-typeglobin genes have provided much insight into the
mechanism(s) of globin gene switching. Mice containing the entire P-globin locus as a
yeast artificial chromosome (PYAC) transgene show correct developmental expression
and silencing of human globin genes (Gaensler et al., 1993; Peterson et al., 1993a;
Peterson et al., 1993b; Zucker et al., 1983). In addition, mice transgenic with smaller
globin gene constructs show similar developmental regulation (Stamatoyannopoulos and
Grosveld, 2001). These transgenic studies have brought about the concept of competitive
and autonomous silencing of globin genes. High level expression of globin genes is
mediated by an enhancer located 5' of the human €-globin gene termed the locus control

region (LCR). In the competition model, two globin genes compete .the enhancer activity
of the LCR with one gene being highly expressed at the expense of the other. In the
absence of another globin gene, the less competitive gene would still be expressed. In the
case of autonon~oussilencing, the gene would not be expressed even in the absence of
other globin genes. The fetal y-globin gene has been shown to be regulated by a
conibination of autonomous silencing and competition. This means y-globin transgenic
mice in the absence of other globin genes decrease expression of the transgene during
development, but cannot completely silence the gene without another globin gene present
(Behringer et al., 1990; Dillon and Grosveld, 1991; Enver et al., 1989; Enver et al., 1990;
Zucker et al., 1983). In the case of the c-globin transgenic mice, the gene is silenced in
the absence of other globin genes and is thus autonomously silenced (Raich et al., 1990;
Shih et al., 1990).
The autonomous silencing of the €-globin gene has been shown to be mediated by
many different factors binding to different locations around the gene. Both GATA-1 and

YY 1 have been shown to bind to different regions of the €-globin gene and mediate
transcriptional repression (Li et al., 1997; Raich et al., 1995). In addition, a complex was
isolated that bound to two inverted direct repeats of a short motif analogous to DR-1
binding sites for non-steroid nuclear hormone receptors in the region of .the CCAAT box
(Tanimoto et al., 2000). Mutation of these repeats leads to expression of the €-globin gene
in adult PYAC transgenic mice (Filipe et al., 1999; Tanimoto et al., 2000). A complex
binding to this site, termed DRED, was found to contain the nuclear orphan receptors

TR2 and TR4 (Tanabe et al., 2002). Thus, it appears many factors contribute to the
autonomous silencing of the e-globin gene during development in transgenic mice.
Globin genes have also been shown to be regulated by DNA methylation. The
first correlation between transcriptional status and DNA methylation in vertebrates was
seen in the avian globin locus (McGhee and Ginder, 1979). Further studies showed a
similar correlation in other species and model systems (Atweh et al., 2003; Mavilio et al.,
1983; Shen and Maniatis, 1980; van der Ploeg and Flavell, 1980). The compound 5azacytidine inhibits the enzyme DNA methyltransferase and leads to a decrease in DNA
methylation levels. Treatment with 5-azacytidine has been shown to induce the
expression of silenced embryonic and fetal P-type globin genes in many different model
systems and in patient studies (Charache et al., 1983; DeSimone et al., 1982; Ginder et
al., 1984; Ley et al., 1982; Ley et al., 1984; Pace et al., 1994; Zucker et al., 1983). A
family of proteins has been identified that bind to methylated DNA and recruits
transcriptional repression complexes, which include histone deacetylases (Feng and
Zhang, 2001; Jones et al., 1998; Nan et al., 1993; Nan et al., 1998; Zucker et al., 1983).
One member of this family is the methyl binding domain protein 2, MBD2. MBD2 has
been shown to bind to a methylated p-globin construct as a large complex containing
histone deacetylase 1 (Singal et al., 2002). In addition, short chain fatty acids, compounds
known to inhibit histone deactylases among other functions, have been shown to induce
the expression of embryonic and fetal P-type globin genes (Dempsey et al., 2003;
Gabbianelli et al., 2000; Little et al., 1995; Marianna et al., 2001; Pace et al., 2002;
Skarpidi et al., 2003; Stamatoyannopoulos and Grosveld, 2001 ; Zucker et al., 1983).

Thus, in addition to factors mediating autonomous and competitive silencing, epigenetic
modifications contribute to globin gene silencing.
Herein we describe a role for both DNA methylation and MBD2 in mediating
human €-globin silencing in adult transgenic mice. Transgenic mice containing
continuous sequence from 5' of HS5 of the LCR through various lengths 3' of the E globin polyA site correctly silence the transgene during development. This silencing is
correlated with low levels of DNA methylation in the embryonic yolk sac and high levels
in adult erythrocytes. Adult transgenic mice treated with 5-azacytidine express the
normally silenced transgene. Furthermore, adult transgenic mice null for MBD2 also
express the transgene. However, PYAC transgenic mice treated with 5-azacytidine or null
for MBD2 express very low levels ;f the €-globin gene. These results indicate that
competition may be necessary to silence the €-globin gene during 5-azacytidine treatment
or in the absence of MBD2.

Methods
Generation of Transgenic Mice
Transgenic mice were generated using two different constructs derived from the
cosmid cosLCR6 (a generous gift from Frank Grosveld) that contain the entire sequence
from 5' of HS5 of the LCR through 12 kb 3' of the human €-globin gene polyA site. A 28
kb construct was generated by digesting cosLCR6 with Not1 and BstBI to release a
fragment containing 4 kb of the 3' sequence. The constructs were run on a low-melting
0.6% agarose gel and gel purified using the Bio 101 Gene Clean Spin Kit (Qbiogene).

Constructs were then injected into fertilized eggs and implanted into pseudopregnant
mothers to generate transgenic mice. Founders were determined by performing PCR on
tail snipped DNA. Primers used to screen LCREmice are shown in Table 7. Three lines
were established for each construct.

Copy Number Determination
Genomic DNA was isolated from tails of positive mice. The DNA was digested
with EcoRI and transferred to a nylon membrane. The blot was probed with a 600 bp
fragment binding to the 3' end of the 3.7 kb portion of the human €-globin gene. The
intensity of this band was compared to EcoRI digested negative mouse genomic DNA
containing 2,5, 10,20, and 40 copies of the LCREcosmid.

Expression Profile of Mice
The developmental regulation of the transgene in mice was determined by
analyzing expression of the transgene at different developmental stages. Timed matings
were performed as described in Chapter 2. RNA was extracted from 10.5 dpc yolk sacs,
14.5 dpc fetal livers, and peripheral blood from adult anemic mice. RNase protection
assays were used to analyze human €-globin mRNA expression. RPA probes protecting
either exon 1 or exon 3 of the human e-globin gene were used for analysis.

Generation of 28kb LCRdMBD2-I- Mice

28kb LCRE mice from lines 1 and 2 were used to generate transgenic knock-out
mice. As performed in Chapter 2, transgenic mice were bred with knock-out mice to
generate hemizygous transgenic mice. These mice were bred with MBD2-I- mice to
generate 28 kb LCRdMBD2-I- mice. Mice were screened for the presence of the
transgene and absence of MBD2 by PCR of DNA from tail snips. Primers used to screen
these mice are in Table 2 and 6.

Treatment of Mice
Mice were treated for two days with intraperitoneal injection of 1-acetyl2-phenylhydrazine (10 mg/mL, Sigma) at a dose of 0.4 mgIl0g. On the third day, mice
were treated with 5-azacytidine (0.5 mgImL, Sigma) at a dose of 2 mglkg for five days
via intraperitoneal injection.

Bisulfite Conversion
EcoRI digested genomic DNA (1 pg) from adult anemic spleens and 10.5 dpc
yolk sacs was diluted to 18 pL in water, boiled for 5 minutes and further denatured by
treating with 2 pL fresh 2N NaOH at 37°C for 15 minutes. Sodium bisulfite solution was
prepared by dissolviiig 1.9 g sodium bisulfite in 2 mL water and 400 pL 2N NaOH and
dissolving 100 mg hydroquinone in 2 mL water. After mixing the solution, 1 mL of the
hydroquinone solution was added to the sodium bisulfite solution. The solution pH was
adjusted (if necessary) to pH 5.0. After denaturing the DNA, 130 pL of the bisulfite
solution and 2 pg tRNA was added and the solution incubated in the dark for 4 hours at

Primer

Sequence

El 1

CTCCCCTTCACCGAATCTCATCC

HBE 1202

CTTAGCGCTTCCAGCTCTACTCCACTG

Table 7:Primers used to screen LCREtransgenic mice.

55"C. After incubation, add 5X volume of Buffer PB (Qiagen) and 30 pL 3M sodium
acetate (pH 5.2) was added to the sample and the solution applied to a spin column
containing 20 pL sodium acetate. Columns were spun at 10000 xg for 1 minute and the
flow-through discarded. Column was washed with 700 pL Buffer PE and centrifuged
again. The sample was eluted by adding 40 pL Elution Buffer, incubating at room
temperature for 5 minutes, and centrifuging. The sample was desolfonated by addition of
4.4 pL 3M NaOH and incubated at 3 7 C for 15 minutes. The sample was precipitated by
addition of 28 pL 5 M ammonium acetate (pH 7.0), 2 pL pellet pain, 2 pg tRNA, and 180

pL ethanol. Sample was then centrifuged for 10 minutes at 10500 rpm at 4' C. The final
pellet was resuspended in 100 pL Elution Buffer.

Single Nucleotide Primer Extension
The DNA methylation status at a single CpGs was determined using single
nucleotide primer extension (SNuPE). Primer extension was performed using nested PCR
product from bisulfite converted DNA as a template. Primers were designed to 1
nucleotide upstream of the CpG of interest. Primer extension was performed using CX-~*P
dCTP or TTP (MP Biomedicals) in separate reactions. Primer extension was performed
by heating at 95' C for 1 minute, annealing for 2 minutes, and extension at 72' C for 1
minute. Only methylated CpGs will incorporate the dCTP while only unmethylated
template will incorporate TTP. The reaction was terminated by adding RPA loading
buffer. The products were analyzed on a 15% polyacrylamide gel after heating at 90' C
for 5 minutes. The gel was exposed to X-Ray film and bands were quantitated using a

phosphor-imager. The percentage of methylation at each site was determined by ,the
following formula: intensity of dCTP band / (intensity of dCTP band

+ intensity of TTP

band). The primers used for bisulfite specific PCR and SNuPE assay are listed in Table 8.

Chromatin Irnmunoprecipitation
Performed as described in Chapter 2.

Real-time PCR
Real-time PCR was performed as described in Chapter 2. The list of primers and
probes used are listed in Table 5.

Results
Two constructs were used to generate transgenic mice. Both constructs contained
the entire sequence from 5' of HS5 through 12 kb (36kb) and 4 kb (28kb) 3' of the
human e-globin polyA site (Figure 17). Three independent transgenic lines of 36kb and
28kb LCRE were established. Only 36kb LCRE line 1 and 28kb LCRE lines 1 and 2 were
used in this work as 28kb LCRE line three appeared to have the transgene inserted in the
Y-chromosome and similar results were seen with 36kb line 1 and both 28kb lines used.
Previous work with similar human €-globin transgenic mice showed the transgene is
highly expressed in the primitive erythroblasts of the 10.5 dpc yolk sac and appreciably
silenced in the definitive cells of the 14.5 dpc fetal liver (Raich et al., 1990; Shih et al.,
1990). In addition, unlike transgenic mice containing various y-globin constructs, these

Primer

Sequence

Bis-Prim2-194 17

GGAGAATAGGGGGTTAGAAT

Bis-Prim1-19667

CCCTTCATTCCCATACATTAAA

PE-19573

GTTGAGGAGAAGGTTGT

PE-19446

I GGAGAATAGGGGGTTAGAATTT
GAGAGGTAGTAGTATATATTTGTTTT

Table 8: List of primers used for bisulfite specific PCR and SNuPE assay at the c-globin
promoter region.

LCR
LCR

Figure 17: Constructs used to generate LCRE transgenic mice. The constructs only differ
by the amount of sequence 3' of the c-globin polyA site: 12kb for the 36kb construct and
4kb for the 28kb construct.

mice showed complete autonomous silencing in the absence of any other human 0-globin
gene. To determine whether the construct used to generate the 28kb and 36kb LCRE mice
was autonomously silenced, timed matings were performed to analyze expression of the
transgene in 10.5 dpc yolk sacs and 14.5 dpc fetal livers. All timed matings were
performed by breeding a transgene positive male with a non-transgenic female. The
presence of a vaginal plug was designated 0.5 dpc. Positive embryos were determined by
screening placentas for the presence or absence of the transgene by PCR. RNA was
isolated from transgene positive yolk sacs and fetal livers from 36kb LCRE line 1 and
28kb LCRE lines 1 and 2 mice. Expression of the transgene was determined by RNase
protection assay. As shown in Figure 18, the transgene is expressed in 10.5 dpc yolk sac
and becomes silenced by 14.5 dpc. Thus, the 28kb and 36kb LCRE constructs show
correct developmental silencing of the transgene, indicating the constructs contain all
sequences necessary for autonomous silencing. Furthermore, transgene expression cannot
be detected in the peripheral blood of anemic adult mice by RNase protection assay
(Figure 19).
The copy number of the transgenic mice was determined using Southern blotting.
Genomic DNA was isolated from all lines and digested with EcoRI. A standard curve
was generated using the LCRE cosmid at known concentrations mixed with nontransgenic genomic DNA. As shown in Figure 17, line 1 contains -10 copies of the
transgene while line 2 contains -20 copies of the transgene. The 36kb LCRE line 1 mice
contains -25 copies of the transgene (Figure 20).

Figure 18: Developmental silencing of the human c-globin gene in LCRE transgenic
mice. The transgene is expressed in the 10.5 dpc yolk sac erythroblasts and becomes
nearly silent in the erythroid cells of the 14.5 dpc fetal liver.

Figure 19: RPA analysis of human c-globin expression in adult LCRE transgenic treated
with and without 5-azcytidine. No human €-globin mRNA is detected in adult 28kb and
36kb LCRE transgenic mice peripheral blood. Treatment of both lines with 5-azacytidine
induces expression of the normally silent transgene in adult mice peripheral blood. @=Iacetyl-2-phenylhydrazine, aza=5-azacytidine.

Figure 20: Copy number determination of 28kb and 36kb LCRc transgenic mice.
Southern blots were performed to determine the copy number using a probe located at the
3' end of human c-globin gene. The copy number was by comparing signal intensity to a
standard curve of known amounts of cosmid LCRc mixed with transgene negative
genomic DNA.

The inverse correlation between DNA methylation and transcriptional activity
was first shown in vertebrates in the chicken 0-globin locus (McGhee and Ginder, 1979).
In addition, a compound that inhibits the enzyme responsible for DNA methylation
(DNMT) activates silenced embryonic and fetal globin genes in a variety of model
systems, chickens, and patients (Ginder et al., 1984; Ley et al., 1982; Ley et al., 1984;
Nienhuis et al., 1985; Pace et al., 1994). We sought to determine whether 5-azacytidine
could activate the silenced human embryonic globin gene in the context of 28kb and 36kb
LCREtransgenic mice. Adult mice made anemic via 1-acetyl-2-phenylhydrazine
treatment fail to express the transgene as detem~inedby RNase protection assay.
However, after a five day treatment regime with 5-azacytidine, adult 28kb and 36kb
LCREtransgenic mice express the h ~ ~ m c-globin
an
gene (Figure 19 and 2 1). In the work
done by Pace and colleagues, PYAC mice treated with 5-azacytidine express the y-globin
gene, but expression of the human €-globin gene was not measured. Interestingly, we find
that when treated with 5-azacytidine, adult PYAC transgenic mice fail to express the
human €-globin gene as determined by RPA (Figure 22). However, when measured by
real-time PCR, low levels are detectable (Figure 23). The 28kb and 36kb LCRE
transgenic mice contain all necessary regulatory elements needed for autonomous
transgene silencing. However, inhibition of DNA methylation is able to overcome these
repressive elements.
Given the ability of 5-azacytidine to overcome the autonomous silencing
mechanisms of the human e-globin gene in 28kb and 36kb LCRE mice, we sought to look
at the methylation status of CpGs around the promoter and proximal transcribed region of

Figure 21: Real-time PCR analysis of human €-globin expression after treatment with 5azacytidine and loss of MBD2 in LCREtransgenic mice. Wild type 28kb LCRE lines 1
and 2 mice were treated with 5-azacytidine. Expression of the transgene was determined
by real-time PCR using peripheral blood RNA from prior to treatment and after
treatment. Peripheral blood RNA was also collected from both lines of mice in the
MBD2+/- and MBD2-1- background.

Figure 22: RPA analysis of human €-globin expression in m A C transgenic mice treated
with 5-azacytidine. In contrast, 5-azacytidine is able to induce expression of the y-globin
gene in adult PYAC transgenic mice. RPA was performed on peripheral blood of mice
treated with and without 5-azacytidine.

Figure 23: Human €-globin expression in LCRc line 2 and PYAC transgenic mice. The
top panel shows expression levels relative to 1-acetyl-2-phenylhydrazine treatment only.
The bottom panel represents the expression of the transgene relative to yolk sac
expression levels.

the transgene. Previous work in our laboratory has shown a correlation between DNA
methylation in the promoter and proximal transcribed region of the chicken p-globin gene
and the silencing of this gene during development (Ginder et al., 1984; Singal et al.,
1997; Singal et al., 2002). To examine the methylation status of 3 CpGs around the
human €-globin promoter and proximal transcribed region, bisulfite conversion followed
by single nucleotide primer extension was performed. The technique allows for the
determination of the percentage of methylation at any CpG of interest in the genome. The
level of methylation was compared at three different CpGs in 28kb LCRE line 2
transgenic mice in 10.5 dpc yolk sac, adult anemic mice, and adult mice treated with 5azacytidine. The promoter and proximal transcribed region in adult anemic mice is highly
methylated (>90%) at all CpG sites tested (Figure 24). This result is in agreement with
the idea that high levels of DNA methylation correspond to low levels of transcription.
The transgene is highly expressed in the primitive erythroblasts of the 10.5 dpc yolk sac.
At this time, the level of CpG methylation is much lower than in adult mice, -40% at
each site tested. The genomic DNA used in this analysis came from total yolk sac tissue
which contains epithelial cells in addition to erythroid cells. Epithelial cells do not
express globin genes and are presumably highly methylated in the globin locus. In
addition, erythroid cells have been found to only account for -1 1% of the total yolk sac
population (Redmond and Lloyd, 2005). As a result, the level of DNA methylation seen
in the 10.5 dpc yolk sac may in fact be much lower than 40%. Adult mice treated with 5azacytidine show an intermediate level of methylation at each site (-80%). This
correlates with expression data. While 5-azacytidine is able to induce expression of the

Figure 24: MS-SNuPE analysis of DNA methylation levels around the €-globin promoter
and proximal transcribed region. Bisuflite conversion was performed on genomic DNA
from the splenocytes of anemic mice or 10.5 dpc yolk sac. After amplification by PCR,
the DNA methylation levels were analyzed using MS-SNuPE at three sites around the Eglobin promoter and proximal transcribed region in 28kb LCRE mice, mice treated with
5-azacytidine and 10.5 dpc yolk sac erythroid cells.

silenced transgene, it is expressed at a much lower level than in the 10.5 dpc yolk sac
(Figure 23). The compound 5-azacytidine is highly toxic. While the dose administered to
the mice is not fatal, it may be insufficient to produce high enough'levels of
demethylation to recapitulate the level of expression seen in the yolk sac. In addition, 5azacytidine is not specific for the P-globin locus and acts as a global inhibitor of DNA
methylation. Hypomethylated DNA is associated with genetic instability and mice
lacking DNMTs are embryonic lethal presumably due to this instability (Li et al., 1992;
Okano et al., 1999). Cells hypomethylated due to 5-azacytidine treatment may undergo
cell death due to the instability of genome leaving only moderately demethylated cells for
the analysis. Finally, these mice have 20 copies of the transgene and the analysis does not
discriminate between individual transgenes. Thus, the relatively low level of
demethylation seen after 5-azacytidine treatment may be due to the number of copies of
the transgene where only highly demethylated copies are expressing the transgene while
methylated copies do not. This kind of variation on a cell-to-cell basis may account for
the low level of demethylation seen after 5-azacytidine treatment. Taken together, these
results show a positive correlation between the level of unmethylated CpGs around the
human c-globin promoter and proximal transcribed region in 28 kb LCRE line 2
transgenic mice and the level of transgene expression.
Inhibition of DNA methylation leads to expression of the y-globin gene in PYAC
transgenic mice and the human c-globin gene in 28 kb and 36 kb LCRc transgenic mice.
Furthermore, loss of MBD2 leads to expression of the y-globin gene in PYAC transgenic
mice. We sought to determine what impact MBD2 has on maintaining repression of the

human c-globin gene in 28 kb LCREtransgenic mice. Mice null for MBD2 were bred
with mice containing the 28 kb LCRE transgene. The resulting hemizygous mice were
bred with MBD2 null mice again to generate transgenic knock-out mice. As was done
previously, adult mice were made anemic to increase erythropoiesis. Blood was collected
from the tail vein and analyzed by real time PCR. Adult 28kb LCRE transgenic mice null
for MBD2 express the transgene at a level -1 6-45-fold over baseline (Figure 19). The
variation in expression of the transgene between line 1 and line 2 may be due to position
effects due to the location of transgene insertion that were not revealed during 5azacytidine treatment. In addition, the higher copy number of the line 2 mice may be a
rate limiting factor in transcription level. Mice containing the D A C transgene and null
for MBD2 express the y-globin gene and low levels of the human e-globin gene (Figure
20). When standardizing expression to determine the fold induction due to 5-azacytidine
treatment or loss of MBD2, the level of induction is similar in PYAC transgenic mice and
28kb LCREF2 mice (Figure 23). However, when calculating expression relative to yolk
sac expression levels, the human €-globin gene is expressed 15-60-fold higher in LCRE
transgenic mice versus PYAC transgenic mice (Figure 23). This is not surprising as loss
of MBD2 leads to no enrichment in TriMeK4, AcH3, AcH4, and Pol I1 levels at the
human €-globin gene promoter or coding regions (Figure 25). This result supports the
notion that competition also plays a role in the silencing of the human €-globin gene.

LCR

3' HSS

Figure 25: Post-translational histone modification changes around the human €-globin
gene promoter and proximal transcribed region in MBD2+/+ and MBD2-1- adult PYAC
transgenic mice. Relative enrichment values were determined relative to the endogenous
amylase gene to control for loading and IgG values to control for non-specific
immunoprecipitation.

Discussion

Transgenic mice harboring constructs containing the entire sequence from 5' HS5
through 4 kb 3' of the human €-globin gene correctly express and silence the gene during
developnlent. Similar to other human c-globin transgenic mice, the mice generated here
contain all necessary cis elements for autonomous silencing (Raich et al., 1990; Shih et
al., 1990). Many factors have been shown to bind to the human €-globin promoter to
mediate transcriptional repression and activity (Filipe et al., 1999; Li et al., 1998a; Li et
al., 1997; Li et al., 1998b; Peters et al., 1993; Raich et al., 1995; Tanabe et al., 2002;
Tanimoto et al., 2000; Wada-Kiyama et al., 1992). While studies have shown DNA
methylation plays a causative role in the regulation of the chicken embryonic p-globin
gene, little was known of the role of DNA methylation in human €-globin gene regulation
(Ginder et al., 1984; Singal et al., 1997; Singal et al., 2002). Here, we show that
inhibition of DNA methylation leads to expression of a silenced human e-globin
transgene in adult mice. Furthermore, there is an inverse correlation between the level of
DNA methylation around the c-globin promoter and proximal transcribed region and the
level of expression of the transgene. Furthermore, loss of the methyl CpG binding
protein, MBD2, leads to expression of the 28 kb LCRE transgene in adult mice.
Initial studies with human €-globin transgenic mice indicated the gene does not
require the presence of an additional human 0-type globin gene to become fully silenced
during development. This was in contrast to the y-globin gene which requires the
presence of an additional 0-type globin gene to become fully silenced in transgenic mice
(Behringer et al., 1990; Dillon and Grosveld, 1991; Enver et al., 1989; Enver et al.,

1990). The y-globin gene is autoiiomously silenced, but requires competition for the
upstream LCR enhancer for complete silencing. Until now, it was thought that
competition was not needed for the complete silencing of the c-globin gene. We show
that both 5-azacytidine and loss of MBD2 can induce expression of the silenced human Eglobin transgene in LCRE transgenic mice. Using the same conditions, mice containing
the entire 0-globin locus yeast artificial chromosome express 15-60-fold less c-globin
RNA. The presence of additional 0-type globin genes inhibits expression of the human cglobin gene when PYAC transgenic mice lack MBD2 or are treated with 5-azacytidine.
The other globin genes out-compete the c-globin gene for upstream LCR enhancer
activity.
The data presented here suggest the human c-globin gene is silenced by three
mechanisms. First, and most likely strongest, is the autonomous silencing mediated by cis
elements. This appears to be the primary mechanism by which the human c-globin gene
is silenced. Disruption of cis elements leads to significant c-globin expression in adult
mice (Raich et al., 1992; Raich et al., 1995; Tanimoto et al., 2000). In addition to
elements located 5' of the human c-globin gene, we have shown 3' sequences may be
involved. As shown here, 36kb and 28kb LCREtransgenic mice correctly express and
silence the transgene during development. However, two lines of transgenic mice
containing similar 5' sequence and only 100 bp 3' of the polyA site had an embryonic
lethal phenotype (data not shown). The embryos were pale and small in size. We
hypothesized the mice were suffering from an a-thalassemia due to overexpression of the
€-globin chain that prevented normal hemoglobin tetramer formation. To test this

hypothesis, a cosmid containing the entire sequence from 5' of HS5 through 100 bp 3' of
the €-globin polyA site was proposed to be inserted into a specific chromosomal location
in MEL cells. As a negative control, the 28kb construct was to be inserted into the same
chromosomal location to prevent any position effects. Expression analysis was to be
performed to determine whether lack of 3' sequence resulted in expression of the c-globin
gene in adult erythroid cells. However, generation of these cells proved problematic.
Using various transfection mechanisms, large cosmids were unable to be effectively
transfected. Currently, alternative mechanisms are being proposed to determine whether
the 3' silencer exists.
Another layer of silencing is mediated by DNA methylation and MBD2. Loss of
MBD2 or treatment with 5-azacytidine induces expression of the human c-globin gene in
36kb and 28kb LCRE transgenic mice. However, low levels are also seen in PYAC
transgenic mice under the same conditions. This revealed a third layer of silencing,
namely competitive mechanism of human c-globin silencing as PYAC mice express 1560-fold less c-globin mRNA than LCRc mice. The presence of other globin genes or
additional down-steam sequences may prevent an effective interaction between the LCR
enhancer and the c-globin gene in a >15-fold decrease in expression (Figure 26).
However, the effect may be due to sequences present on the PYAC transgene rather than
competition mediating this effect. Taken together, these results indicate the human Eglobin gene is silenced by three mechanisms. We have shown significant expression
when removing two of these mechanisms. An interesting study would be to combine

elements of all three mechanisms to determine what fold repression each exerts on the E globin gene.

LCR

I

Figure 26: Model of e-globin silencing in adult PYAC transgenic mice by sequences
downstream of the €-gene. In the absence of other downstream sequences, loss of MBD2
or treatment with 5-azacytidine allow for an effective interaction between the €-globin
gene and the LCR enhancer leading to transcription of the transgene (top). In PYAC
transgenic mice, the e-globin gene is expressed at a much lower level to disruption of .the
enhancer interaction by other globin genes or downstream sequences (middle and
bottom).

Chapter 4: Mechanism of MBD2 Mediated Repression of the y-globin Gene

Introduction
Adult transgenic mice null for MBD2 express silenced embryonic and fetal globin
genes. The level of induction of the y-globin gene in PYACIMBD2-I- mice is similar to
the level seen in PYAC mice treated with the DNA methyltransferase inhibitor 5azacytidine. In addition, treatment of PYACIMBD2-I- with 5-azacytidine does not
produce an additive induction of y-globin RNA relative to treatment of wild type PYAC
mice. These results indicate that MBD2 and 5-azacytidine work via the same mechanism
to induce globin gene expression. In addition to the work presented here, previous work
has shown treatment with 5-azacytidine leads to hypomethylation around the globin gene
promoters and a concomitant increase in embryonic or fetal globin transcription (Ginder
et al., 1984; Ley et al., 1983; Ley et al., 1984; Zucker et al., 1983). With the discovery of
proteins that specifically bind to niethylated DNA and recruit transcriptional repression
complexes, it seemed a likely hypothesis that these proteins were mediating the
repressive effect seen on genes up-regulated upon DNMT inhibition by binding to
methylated CpGs around the promoter and inhibiting transcription. However, only a
handful of genes have been shown to be bound by MCBPs in vivo in non-cancerous cells

(Chen et al., 2003; Hutchins et al., 2002; Klose et al., 2005; Kransdorf and Ginder, 2004;
Martinowich et al., 2003). The y-globin gene has been reported to be regulated by many
mechanisms including by multiple signaling pathways and by epigenetic modifications
(Bhanu et al., 2004; Bhanu et al., 2005; Pace et al., 2003). Thus, MBD2 mediated
transcriptional repression of the E-and y-globin genes in adult LCRE and PYAC
transgenic may be due to direct recruitment of MBD2 to the E-or y-globin promoter, or
via a cell signaling pathway or both. Therefore, we sought to determine whether MBD2
binds the E-or y-globin promoter in vivo and what gene(s) were aberrantly expressed in
MBD2 null mice that mediated these effects. To do this, chromatin immunoprecipitation
assays were performed to locate where MBD2 was binding to mediate transcriptional
repression of the E- and y-globin genes. Microarray analysis was performed on MBD2+/+
and MBD2-1- mice to determine what genes are differentially expressed in adult erythroid
cells. The data from the microarray was further analyzed using a pathway analysis
program to determine what pathways were differentially impacted due to the loss of
MBD2.

Methods
Chromatin Irnmunoprecipitation
Chromatin immunoprecipitation was performed as described in Chapter 2 with the
following modifications. Chromatin was crosslinked with 1% formaldehyde for 10
minutes at room temperature. Sonication was performed 8x instead of 6x. Chromatin was
washed three times with low salt buffer and one time with medium salt buffer (equal

parts high salt and low salt buffer). Immunoprecipitations were performed with antiMBD2 (Upstate), anti-MBD213 (Upstate), ant-MTA2 (Santa Cruz), goat IgG (Santa
Cruz), sheep IgG, and protein G salmon sperm agarose beads. DNA was analyzed using
real-time PCR and SYBR Green chemistry. Primers used for real-time PCR analysis are
listed in Table 9.
Lower stringency washes were used because DNA binding proteins that are more
difficult to ChIP than histones owing to lower abundance. Thus, to account for increased
non-specific pull-down, enrichment was determined with the following formula:
Sample-(gene boundlinput)/(amylase boundlinput)
IgG-(gene bound/input)/(amylase boundlinput)

Microarray Analysis
Four wild type mice and four MBD2-1- mice were treated with l-acetyl-2phenylhydrazine for two days. Spleens were harvested on the fifth day and RNA isolated
using Trizol. The RNA was treated with DNase I using the Turbo DNase kit (Ambion).
The RNA was further cleaned and concentrated using the RNeasy MinElute Cleanup kit
(Qiagen). The RNA was eluted in DEPC-treated water to which 1 pL of SuperRNasin
was added per 40 pL water. RNA purity was judged by the ratio of absorbance at 260 and
280 nm (A260/ A2*0)and 260 and 270 nm (A2601 A270).In addition, RNA, cDNA, and
cRNA integrity were assessed by running 1 pL of every sample in RNA 6000 Nano or

Primer

Sequence

Ugt8-F-1574

TTAGAGCTCTGAAGGGCATGTGGA

Ugt8ChIP-Probe

6famTGCTCTGCGTCTCCCAAACTCAAGAAtamra

Ugt8-R-1671

TGTGCTAATTCCTCCCGCAACAGA

Gammaprom-ChP-F

CCTTGCCTTGACCAATAGCCTTGA

Gammaprom-ChP-Probe

6famACAAGGCTACTATCACAAGCCTGTGGtamra

Gammaprom-ChP-R

TTCCAGAAGCGAGTGTGTGGAACT

-3.4GATA2F

TCCATCCAGCAGCTTTAGGAA

-3.4GATA2R

GGGTTCGAAGCCACTCCAA

Table 9:List of primers used for real-timePCR for ChP assays in Chapter 4.

Pico LabChips on the 21 00 Bioanalyzer (Agilent) depending on the RNA concentration,
according to manufacturers protocol. RNA (5 pg) was reverse transcribed to cDNA
using a 24-mer oligodeoxythymidylic acid primer with a T7 RNA polymerase promoter
sited added the 3' end of the T7-olidgo(dT) using the Superscript cDNA Synthesis
Systems (Life Technologies). In vitro transcription was performed using the Enzo
BioArray High Yield RNA Transcript Labeling kit (Enzo) to produce biotin-labeled
cRNA. For each sample, 20 pg of the cRNA product was fragmented and hybridized for
18-20 h onto an Affymetrix Genechip 430A 2.0 microarray (Affymetrix). Each
microarray contains 45,000 probes sets analyzing the expression of over 39,000 different
transcripts where one transcript is generally interrogated by more than one probe set.
Each probe set contains probes that either perfectly match (PM) the sequence in a
segment of the target gene or contain a single mismatched (MM) nucleotide in the middle
position of the corresponding perfectly matched probe. The intensity difference of PM
probes and MM probes is used to make detection calls which determine whether the
transcript of a gene is detected or undetected. Each microarray was washed and stained
with streptavidin-phycoerythrin and scanned at a 6 pm resolution with the Agilent
G2500A Technologies Gene Array scanner (Agilent Technologies) according to the
GeneChip Expression Analysis Technical Manual procedures (Affymetrix).
After scanning, the scaling factor, the noise (RawQ) value for a given probe array
hybridization, the percentage of probe sets declared "Present" (%P) by the detection call
algorithm, the 3'15' ratios of the signal intensity values for two house-keeping genes

(GAPDH and 0-actin), and the presence or absence call for the ribosomal RNAs 18s and
28s were determined for quality control purposes.
For every probe set, normalization, background subtraction, and expression
summaries were calculated using three different methods. First the Microarray Suite 5.0
method was used to obtain probe set summaries. Model-based expression indices were
calculated by use of a multiplicative model to account for probe affinity effects in
calculating probe set expression summaries. Lastly, the multiarray average method was
used. This method uses quantile nornlalization followed by a median polish to remove
probe affinity effects when calculating probe set summaries. Only genes significantly
changed using all three methods were used for further analysis. All microarray studies
were performed by Dr. Cathrine Dumur in the Virginia Commonwealth University
Department of Pathology.

Pathway Analysis
To determine whether the differentially expressed genes in the microarray were
impacting cell signaling pathway(s), the gene list was analyzed using the Ingenuity
Pathway Analysis (IPA) program (Ingenuity Systems). Two sets of gene lists were
analyzed using different P-values, <0.005 and <0.01. This program uses the Ingenuity
Pathways Knowledge Base (IPKB) to provide insights into observed gene expression
changes across biological samples. The input to this application corresponds to a user
generated dataset file containing differentially expressed genes. Genes of interest to the
user, that are also known to directly (or indirectly) interact with other genes in the IPKB,

are called Focus Genes and are used to identify molecular networks that indicate how
these genes may influence each other. IPA dynamically computes a large "global"
molecular network based on hundreds of thousands of curated direct and indirect physical
and functional interactions between orthologous mammalian genes from the published,
peer-reviewed content in Ingenuity's Knowledge Base.

CpG Island Determination
The genornic DNA sequence of up-regulated genes from microarray analysis were
obtained from the Mouse Genome Inforniatics web site (http://www.informatics.jax.org/).
This sequence was analyzed with the CpG Island Searcher program using default
parameters (http://cpgislands.usc.edu/).

Real-Time PCR
Candidate genes from microarray analysis were analyzed using real-time PCR to
confirm differences in expression between wild-type and knock-out splenocytes.
Candidate gene were chosen based on the level of significance (P-value <0.01) and
presence in a hematological pathway. RNA from six of the eight mice analyzed in the
microarray was first reverse transcribed using Script (Bio-Rad). Candidate genes were
analyzed using pre-designed Taqman probes sets (Applied Biosystems) or SYBR Green
chemistry with pre-designed primer sets (Wang and Seed, 2003). All values were
standardized using mouse cyclophilin A as an internal control. Primers used for real-time
PCR analysis are located in Table 10.

Primer

Sequence

BAF57-114-F

AAAAGACCATCTTATGCCCCAC

BAF57-114-R

CCTGTAGTTGTTGTAGGCGAG

Ugt8-121-F

ACTCCATATTTCATGCTCCTGTG

Ugt8-121-R

AGGCCGATGCTAGTGTCTTGA

ROG-101 -F

GCTCTGAGAGAGGACTTGGGA

ROG-101-R

TGCTTTATGCTTGTGTGACATCT

mCyclophilinA-F

GAGCTGTTTGCAGACAAAGTTC

mCyclophilinA-R

CCCTGGCACATGAATCCTGG

Jund 1

ABI Part #: Mm01343 193-sl

MAPK3

ABI Part #: Mm01973540-gl

Table 10:Primers used for real-timePCR validation of microarray results and
confirmation of MBD2 knock-down.

Results
The promoter region of the y-globin gene does not contain a CpG island. In fact,
no region of .the promoter contains more than 4 CpGs within a 70 bp span. Preliminary
C h P results indicated MBD2 was not bound to the promoter region of the y-globin gene,
but was slightly enriched in the 5' region of the GATA2 gene (Figure 27). Taken
together, these results led us to believe MBD2 was not mediating its repressive effect by
binding to the y-globin promoter region. Studies in cell culture lines and primary human
erythroid cells have shown cell signaling pathways play a role in y-globin transcriptional
regulation (Bhanu et al., 2004; Bhanu et al., 2005; Ikuta et al., 2001; Pace et al., 2003).
Thus, we postulated MBD2 may be differentially regulating a factor needed for y-globin
activation directly or by regulating a factor in a signaling pathway necessary for y-globin
transcriptional activation. To determine which gene(s) were involved, microarray
analysis was performed. Four wild-type and four MBD2 knock-out mice were made
anemic by 1-acetyl-2-phenylhydrazine treatment. Spleens were harvested on the fifth or
seventh day and RNA isolated. After amplification, the RNA was hybridized to the
Affymetrix 430A2.0 mouse microarray chip. ANOVA analysis on each probe set
identified -25 genes upregulated significantly (p<0.005) in MBD2-1- erythroblasts and
266 genes differentially regulated using significant but less stringent analysis (p<0.01)
(Table 11). Upon initial observation, there was no known erythroid specific factor that
was up- or down-regulated in MBD2-/- erythroblasts. However, almost every gene
upregulated in MBD2-/- cells contained a CpG island (Table 12) using the default
settings of the CpG Island Searcher Program (http://cpgislands.usc.edu/).

LCR

3' HSS

Figure 27: Determining in vivo binding of MBD2 using the ChIP assay. ChIP assays were
performed using anti-MBD2, ant-MTA2, and sheep and goat IgG antibodies. DNA was
analyzed using real-time PCR at the human E - and y-globin promoters, a weak CpG
island between the y-globin and 6-globin genes, the human 0-globin coding region, the
Ugt8 gene CpG island, the ROG gene CpG island, and the upstream region of the
GATA2 gene. Data was normalized to endogenous amylase levels to account for loading
errors and IgG to account for non-specific pull-downs.

Fold difference
-6.10
1.97
-1.56
-2.67
-6.45
-3.40
2.53
-4.74
-1.34
1.71
-1.47
2.19
5.71
1.47
1.69
-1.37
1.21

Gene
methyl-CpG binding domain protein 2
inositol polyphosphate-5-phosphatase B
tripartite motif protein 30-like
apolipoprotein B editing complex 3
3-phosphoglycerate dehydrogenase
RIKEN cDNA 26 10034N03 gene
histoconlpatibility 28
tripartite motif protein 12
tyrosyl-tRNA synthetase
RAB3A interacting protein
RAP2B, member of RAS oncogene family
expressed sequence C79248
UDP-glucuronosyltransferase 8
tropomodulin 4
G kinase anchoring protein 1
RIKEN cDNA 2410026K10 gene
LanC (bacterial lantibiotic synthetase component C)-like 1
16 days neonate thymus cDNA, RIKEN full-length
enriched library, clone:A130032A08 product:
unclassifiable, full insert sequence
cell division cycle associated 3
cDNA sequence BC004690
tripartite motif protein 34

2.06
-1.69
-4.42
-4.61
-6.54
&
1.90
cysteine-rich protein 1 (intestinal)
hairylenhancer-of-split related with YRPW motif 2
1.17
solute carrier family 35 (UDP-glucuronic acid/UDPN-acetylgalactosamine dual transporter), member D l
2.78
stearoyl-Coenzyme A desaturase 2
2.57
interferon-induced protein 44
2.56
1.61
RIKEN cDNA 2610034N03 gene
3-hydroxyisobutyryl-Coenzyme A hydrolase
-1.62
MAS 1 oncogene
1.14
receptor-like tyrosine kinase
1.81
RIKEN cDNA 6720467C03 gene
-3.47
transcriptional regulator, SIN3B (yeast)
1.14
receptor-like tyrosine kinase
1.70
2'-5' oligoadenylate synthetase 1D //I 2'-5' oligoadenylate
1.58

1.13
-1.56
-1.29
2.1 1
2.00
-1.71
-4.57
1.15
-1.31
-2.01
1.58
-1.21
-1.67
-1.99
1.53
1.17
-6.33
1.89
-1.36
-2.58
-1.08
1.15
-1.36
1.12
-1.65
1.33
-1.26
-1.74
-2.68
1.87
2.02
-1.22
1.35
-1.21
1.50
-1.18
1.41
1.17
-1.20
1.12

synthetase 1E
RIKEN cDNA 201 0002A20 gene
pan hematopoietic expression
RIKEN cDNA 25 10015F01 gene
zinc finger, FYVE domain containing 21
zinc finger, FYVE domain containing 2 1
RIKEN cDNA 25 10048K03 gene
expressed sequence A1447904
RIKEN cDNA 2300006M17 gene
cDNA sequence BC028528
RIKEN cDNA 9 130208E07 gene
histidyl-tRNA synthetase
expressed sequence AW060207
polymerase (DNA directed), delta 2, regulatory subunit
RIKEN cDNA 1810010014 gene
suppressor of Ty 16 homolog (S. cerevisiae)
thioredoxin 2
methyl-CpG binding domain protein 2
transcription factor 7-like 2, T-cell specific, HMG-box
deleted in polyposis 1
RNA-binding region (RNP1, RRM) containing 2
RIKEN cDNA 1700001E 16 gene
signal recognition particle receptor, B subunit
glycyl-tRNA synthetase
solute carrier faniily 39 (zinc transporter), member 9
serine hydroxymethyl transferase 2 (mitochondrial)
DEAD (Asp-Glu-Ala-Asp) box polypeptide 19 ///
RIKEN cDNA 28 10457M08 gene
3-ketoacyl-CoA thiolase B
RIKEN cDNA 18 1001 0 014 gene
Diabetic nephropathy-related gene 1 mRNA, partial sequence
phytanoyl-CoA hydroxylase
GTP cyclohydrolase 1
cell division cycle 26
5-azacytidine induced gene 2
RIKEN cDNA 8430432M10 gene
cDNA sequence BC002199
expressed sequence 2 embryonic lethal
cardiac lineage protein 1
RIKEN cDNA 4932432K03 gene
hemoglobin alpha, adult chain 1
RIKEN cDNA 1110028N05 gene

2.14
-2.08
1.71
-1.64
-1.21
-1.19
1.31
-3.02
-1.12
1.76
1.51
-1.29
-1.89
1.41
2.02
-1.79
-1.18
1.60
-2.26
1.76
1.52
-1.60
-1.39
1.12
1.37
-1.18

-

-1.21
1.29
-1.69
1.10
-1.16
1.24
-1.61
1.64
1.55
-1.18
-1.44
-2.92
1.19

myelin basic protein
kinesin family member 5B
tripartite motif protein 34
membrane-associated protein 17
RIKEN cDNA C730025P13 gene
expressed sequence AU040320
thioredoxin 2
DNA segment, Chr 7, ERATO Doi 760, expressed
coiled-coil-helix-coiled-coil-helix domain containing 5
RIKEN cDNA 3 110007P09 gene
RIKEN cDNA 1110053F04 gene
RIKEN cDNA 26 10001E 17 gene
runt related transcription factor 1
cDNA sequence ~ C 0 5 3 9 1 7
ROD1 regulator of differentiation 1 (S. pombe)
DNA-damage inducible transcript 3
epidermal growth factor-containing fibulin-like extracellular
matrix protein 1
solute carrier family 1 (glutamatelneutral amino acid
transporter), member 4
secreted acidic cysteine rich glycoprotein
tyrosine kinase, non-receptor, 1
spermatogenesis associated 13
glutathione S-transferase omega 1
tripartite motif protein 24
RIKEN cDNA E030006K04 gene
ubiquitin carboxyl-terminal esterase L5
regulatory factor X-associated ankyrin-containing protein
restin (Reed-Steinberg cell-expressed
intermediate filament-associated protein)
leucine-rich repeats and immunoglobulin-like domains 1
RIKEN cDNA 23 10057G13 gene
cDNA sequence BC019537
crumbs homolog 1 (Drosophila)
casein kinase 1, alpha 1
ubiquitin C
DNA segment, Chr 8, ERATO Doi 354, expressed
RIKEN cDNA 2610034N03 gene
KDEL (Lys-Asp-Glu-Leu) containing 1
RIKEN cDNA 2410026K10 gene
coproporphyrinogen oxidase
thioredoxin 2

1.26
-1.37
-1.31
-2.48
1.37
1.44
-1.16
1.39
6.42
-1.28
-1.96
-1.31
1.28
1.46
-1.53
-1.18
-1.49
1.44
-1.32
1.20
-1.74
1.29
-2.01
1.22
1.17
2.03
-1 -06
1.16
1.40
1.17
-1.83
-1.21
-1.65
1.79
1.14
1.64
-1.31
1.32
1.29

zinc finger protein X-linked
RIKEN cDNA 1200006F02 gene
sphingosine kinase 1
RlKEN cDNA 9830147J24 gene
SWUSNF related, matrix associated, actin
dependent regulator of chromatin, subfamily e, member 1
HIV- 1 Rev binding protein
Ceruloplasmin
Rho guanine nucleotide exchange factor (GEF) 12
microfibrillar-associated protein 1
cDNA sequence BC011467
tripartite motif protein 34
RIKEN cDNA 3 110005G23 gene
2'-5' oligoadenylate synthetase 1E
SUMOIsentrin specific protease 2
membrane-associated protein 17
RIKEN cDNA 1110014L17 gene
phosphoinositide-3-kinase, class 3
SUMOIsentrin specific protease 2
diptheria toxin resistance protein required for
diphthamide biosynthesis (Saccharomyces)-like 1
protein phosphatase 2a, catalytic subunit, beta isoform
deanlinase domain containing 1
interferon alpha responsive gene
growth arrest and DNA-damage-inducible 45 alpha
spectrin beta 2
rabaptin, RAE3 GTPase biildiilg effector protein 1
Clone L2MZB- 13.5 immui~oglobulinheavy chain variable
region mRNA, partial cds
DnaJ (Hsp40) homolog, subfamily C, member 4
phosphate cytidylyltransferase 2, ethanolamine
TRAF family member-associated Nf-kappa B activator
protein phosphatase 1, catalytic subunit, gamma isoform
RIKEN cDNA 23 10009N05 gene
F-box only protein 3 1
zinc finger protein 3 86 (Kruppel-like)
cDNA sequence BC008 163
casein kinase 11, alpha 2, polypeptide
CCR4 carbon catabolite repression 4-like (S. cerevisiae)
phosphomannomutase 1
adaptor-related protein complex 3, mu 1 subunit
UDP-glucose pyrophosphorylase 2

-1.80
1.55
1.28
1.58
-3.40
1.25
1.27
1.40
-1.12
1.41
1.43
1.08
4.32
-1.09
-2.40
2.40
1.18
1.34
1.93
1.20
1.63
1.68
-1.14
1.64
-1.18
1.22
1.47
1.79
1.22
1.31
-1.07
1.47
1.20
-2.61
1.34
-1 -25
1.44
-1 -44
1.25
1.53

ubiquitin C
low density lipoprotein receptor-related protein associated protein 1
Sjogren syndrome antigen B
Similar to PCAF acetyltransferase; p300lCBP-associated
factor (LOC330129), mRNA
guanylate nucleotide binding protein 2
RIKEN cDNA 6820402020 gene
zinc finger, CW-type with coiled-coil domain 3
eukaryotic translation initiation factor 3, subunit 1 alpha
Similar to ubiquitin A-52 residue ribosomal protein fusion
product 1 (LOC383341), mRNA
Janus kinase 1
Ninein
RIKEN cDNA 63305 12M04 gene
microfibrillar-associated protein 1
nuclear receptor subfamily 2, group C, member 1
3-phosphoglycerate dehydrogenase
microfibrillar-associated protein 1
growth factor receptor bound protein 2-associated protein I
ribulose-5-pliosphate-3-epimerase
cyclin M2
Rab geranylgeranyl transferase, a subunit
GTP cyclohydrolase 1
lipocalin 7
Era (G-protein)-like 1 (E. coli)
camitine acetyltransferase
nurim (nuclear envelope membrane protein)
RIKEN cDNA 1810017G16 gene
RIKEN cDNA 2700084L22 gene
adaptor-related protein complex 3, mu 1 subunit
RIKEN cDNA 23 10020A21 gene
RIKEN cDNA 26 10020H15 gene
PYD and CARD domain containing
DNA segment, Chr 16, ERATO Doi 480, expressed
pregnancy-specific glycoprotein 23
purine-nucleoside phosphorylase
topoisomerase (DNA) I
Clone IMAGE:3983419, mRNA
expressed sequence C78339
nucleotide binding protein 2
Itchy
RIKEN cDNA 4833415E20 gene

-

-1.53
1.80
1.53
1.31
-1.50
-3.13
1.42
1.18
1.38
-1.35
-1.30
-2.46
-1.30
-1.36
-1.31
1.46
-1.18
1.67
-2.87
-1.19
1.57
1.19
1.52
1.31
1.41
2.11
-1.41
1.99
1.30
1.11
-1.60
1.30
1.26
1.22
1.31
1.33
1.22
-1.61
1.12
1.33
1.15

fibulin 5
peptidase 4
tripartite motif protein 25
nudix (nucleoside diphosphate linked moiety X)-type motif 4
synaptogyrin 1
purine-nucleoside phosphorylase
niban protein
ribonucleotide reductase M2
HIV- 1 Rev binding protein
scavenger receptor class B, member 2
RIKEN cDNA D230019K24 gene
lymphocyte antigen 6 complex, locus A
eukaryotic translation initiation factor 3, subunit 8
Jun proto-oncogene related gene d l
palmitoyl-protein thioesterase 2
procollagen, type V, alpha 1
RIKEN cDNA 1110035L05 gene
aminopeptidase puromycin sensitive
CD5 antigen-like
RIKEN cDNA 1200014P03 gene
hypothetical protein A1 30072507
RIKEN cDNA 23 10037124 gene
vesicle-associated membrane protein 3
nuclear transport factor 2
platelet-activating factor acetylhydrolase, isoform 1b, alpha2 subunit
repressor of GATA
solute carrier family 12, member 2
glioblastoma amplified sequence
protein phosphatase 4, regulatory subunit 2
solute carrier family 13 (sodium-dependent
dicarboxylate transporter), member 3
DnaJ (Hsp40) homolog, subfamily D, member 1
UDP-N-acetylglucosamine pyrophosphorylase 1
protein kinase, lysine deficient 1
SUMO1Isentrin specific protease 1
RIKEN cDNA 3300001P08 gene
zinc finger, CW-type with coiled-coil domain 3
interferon (alpha and beta) receptor 2
pyruvate dehydrogenase kinase, isoenzyme 1
cellular nucleic acid binding protein 1
ubiquitin-conjugating enzyme E2, J1
LIM domain only 7

serine (or cysteine) proteinase inhibitor, clade G, member 1
-1.72
RIKEN cDNA 28 10055E05 gene
1.26
adducin 1 (alpha)
1.37
Table 11: List of all genes differentially regulated in MBD2-1- mice from microarray
Analysis at P<0.01.

Gene Symbol

Gene

UDP-glucuronosyltransferase 8
Kinesin family member 24
Solute carrier family 35

Slc35dl

GTP cyclohydrolase 1

Gch 1

Regulator of differentiation 1

I

Rod1

Inositol polyphosphate-5-phosphatase B

Inpp5b

Cysteine-rich protein 1

Crip 1

Transcription factor 7-like 2

Tcfll2

Recptor-like tyrosine kinase

R Y ~

I

I

RAB3A interacting protein
RAB3A interacting protein
Procollagen, type V, alpha 1
Crystallin, lamda 1
SUMOIsentrin specific protease 2

I
Table 12: List of genes significantly up-regulated in the absence of MBD2 possessing a
CpG island (P<0.005).

No gene from the high specificity list (p<0.005) appeared to be an erythroid
specific factor. Therefore, we analyzed both lists using the Ingenuity Pathway Analysis
(IPA) program to discern the impact of MBD2 on known cellular pathways. This
program uses the Ingenuity Pathways Knowledge Base (IPKB) to provide insights into
observed gene expression changes across biological samples. The input to this application
corresponds to a user generated dataset file containing differentially expressed genes.
Genes of interest to the user, that are also known to directly (or indirectly) interact with
other genes in the IPKB, are called Focus Genes and are used to identify molecular
networks that indicate how these genes may influence each other. IPA dynamically
computes a large "global" molecular network based on hundreds of thousands of curated
direct and indirect physical and functional interactions between orthologous mammalian
genes from the published, peer-reviewed content in Ingenuity's Knowledge Base.
Analysis of both data sets (P<0.005 and 0.01) identified several genes in known
hematologic pathways (Figure 28). We analyzed four genes by real-time PCR we thought
may represent candidate genes from these pathways: mitogen activated protein kinase 3
(MAPK3), zinc finger and BTB domain containing protein 32 (TZFP), jun protooncogene related gene d l (JunDl), and SwiISNF related, matrix associated, actin
dependent regulator of chromatin, subfamily e, member i (Baf57). As a positive control,
the gene having the highest fold difference between knock-out and wild type cells, UDP
galactoyltransferase 8A (Ugt8), was also analyzed. As shown in Figure 29, only TZFP
and Ugt8 were upregulated in MBD2 null mice. This result indicates the importance of
confirming the results of microarray analysis especially

Figure 28: Hematological pathway identified by Ingenuity Pathway Analysis software.
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Figure 29: Validation of potential candidate genes by real-time PCR. The results shown
are the average of three mice of each phenotype. The RNA used for this validation is the
same used for the microarray analysis.

when lowering the P-value for analysis purposes. TZFP was found to be increased >20fold in MBD2-I- erythroblasts. TZFP is also known as repressor of GATA (ROG), PLZFlike zinc finger protein (PZLP) and Fanconi anemia zinc finger (FAZF). TZFP is a POZ
(POZ and Kriippel) protein containing three C2-H2Kriippel-type zinc finger domains and
has been shown to heterodimerize with FANC-C and PLZF and is therefore proposed to
play a role in Fanconi's anemia and acute promyelocytic leukemia (APL) (Hoatlin et al.,
1999). In addition, TZFP has been shown to interact with GATA-2, although the effect of
the interaction has not been determined (Tsuzuki and Enver, 2002). GATA-2 has been
shown to upregulate y-globin expression in K562 cells (Ikonomi et al., 2000).
Interestingly, a CpG island is located just 3' of the TZFP gene and just upstream of the
MLL2 gene. Taken together, these results implicate TZFP as a possible candidate gene
for the upregulation of the y-globin gene in MBD2-I- mice.
Preliminary results indicated MBD2 does not bind to the y-globin promoter region
to mediate a repressive effect. In addition, the CpG island content of the locus was
analyzed. Only two weak CpG islands were found, but they were not located near any
gene within the locus. To determine whether MBD2 was recruited to one of these weak
CpG islands, ChIP was performed. No enrichment for MBD2 was seen at the island
located between the y- and 6-globin genes (Figure 27). Furthermore, no enrichment was
seen at the c-globin gene promoter region or at the human P-globin transcribed region.
The same data seemed to indicate that MBD2 was bound to the GATA-2 upstream region
similar to results seen in MEL cells (Rodriguez et al., 2005). However, the level of
enrichment seen is not very high. The microarray data provides the opportunity to define

a strong positive control to confirm the initial MBD2 ChIP studies. The genes upregulated in MBD2-/- erythroblasts are presumably primarily regulated by MBD2. In
addition, most genes up-regulated by MBD2 in knock-out splenocytes contains a CpG
island (Table 12). Thus far, only one gene has been shown to be up-regulated in the
absence of MBD2 in mice and the study was performed in Thl and Th2 lymphocytes
(Hendrich et al., 2001). No studies have been focused on the genes regulated by MBD2 in
erythroid cells. As a result, MBD2 recruitment to the Ugt8 CpG island was analyzed by
real-time PCR. Ugt8 displayed the highest fold difference between MBD2-I- and
MBD2+/+ erythroblasts in microarray analysis and was confirmed to be expressed -4fold higher in MBD2-I- cells. ChIP analysis showed MBD2 to be recruited to the Ugt8
CpG island in wild-type but not knock-out splenocytes suggesting MBD2 mediates a
transcriptional repressive effect directly at the Ugt8 (Figure 27). This is in contrast to
what occurs at the y-globin gene. Loss of MBD2 leads to increased transcription, but
MBD2 does not bind directly to the y-globin promoter region to mediate the effect. The
Ugt8 ChIP data validates the result that MBD2 does not bind to the y-globin promoter in
addition to validating the ability of the microarray to identify genes regulated by MBD2.
In addition, MBD2 enrichment is seen at the CpG island located 3' of the TZFP gene. As
another control, MBD2 was not enriched at the highly expressed human P-globin gene.
To further confirm the result .that MBD2 does not bind to the y-globin promoter
region, ChIP was performed with an ant-MBD213 antibody. No enrichment is seen at the
y-globin promoter while enrichment is seen at the CpG islands near the Ugt8 and TZFP
gene (Figure 27). Thus neither MBD2 nor MBD3 are binding near the y-globin promoter.

ChIP was also performed with an anti-MTA2 antibody. MTA2 is part of the NuRD
complex which associates with MBD2. MTA2 is not recruited to the y-globin promoter
but is recruited to the Ugt8 and TZFP CpG islands.

Discussion
Loss of MBD2 leads to expression of the normally silent fetal globin gene, y, in
adult PYAC transgenic mice. MBD2 mediated transcriptional repression is thought to
occur via MBD2 recruitment to methylated CpGs in the promoter region of a gene.
MBD2 may bind as a complex or once bound recruit a protein complex to repress
transcription via HDACs and transcriptional repressive proteins. To determine whether
MBD2 represses the human y-globin gene in adult PYAC transgenic mice, ChIP assays
were.performed to determine whether MBD2 binds to the y-promoter region in vivo. No
enrichment was found for MBD2 at the y-globin promoter region in wild-type or MBD2
null splenocytes using two different antibodies. However, MBD2 is enriched in wildtype, but not knock-out, splenocytes at the GATA2 upstream promoter, the Ugt8 CpG
island, and the CpG island 3' of the TZFP gene. This result is not surprising despite the
high level of CpG methylation in adult erythroblasts. The y-globin gene does not contain
a CpG island. While MBD2 can bind to as few as 3 CpGs in vitro, this has not been
shown in vivo nor has it been shown whether MBD2 can bind as a complex to a region
with low CpG density. MBD2 binding has been shown to increase with increasing CpG
density (Kransdorf and Ginder, 2004). The MBD2 containing complex, MeCP1, is able to
bind sparsely methylated DNA but it is unstable and its repressive properties can be

overcome by a strong enhancer, similar to the LCR (Boyes and Bird, 1992). Taken
together, it is not surprising that MBD2 mediated transcriptional repression of the yglobin gene is not due to MBD2 recruitment to the y-globin promoter region.
Studies have shown that mechanisms other than simple cis element trans factor
binding to the y-promoter exists for y-globin gene regulation. We postulated that MBD2
mediated y-globin gene silencing may be due to up-regulation of a factor that binds to the
y-promoter region or a factor involved in a signaling pathway needed for y-globin
activation. As a result, we performed a microarray analysis of erythroblasts from four
MBD2+/+ and four MBD2-I- mice. No erythroid specific factors were identified on the
initial highly significant (p<0.005) gene list generated by microarray analysis. However,
after analyzing the gene lists through the Ingenuity Pathway Analysis program, several
genes involved in hematologic pathways were identified. One of these genes, TZFP, was
found to be >20-fold enriched in MBD2-I- erythroid cells. This protein appears to be a
potential candidate for MBD2 mediated y-repression. This protein has been shown to
interact with GATA-2, but its effect on GATA-2 activity has not been determined
(Tsuzuki and Enver, 2002). Overexpression of Gata-2 in K562 cells leads to increased
expression of the y-globin gene (Ikonomi et al., 2000). TZFP may interact with Gata-2 to
promote y-globin gene expression, however further experiments must be performed to
prove or disprove this hypothesis. Interestingly, the TZFP gene does not contain a CpG
island in its 5' promoter region, but does contain a CpG island 3' of the coding sequence,
but 5' of the downstream MLL2 gene. We have shown MBD2 is recruited to this island.

Given the large induction of TZFP expression in the absence of MBD2, this CpG island
may be mediating a novel 3' repressive effect on TZFP.
The results described here show the importance of validating candidate genes
acquired from niicroarray analysis. Three genes considered to be potential candidates did
not show a difference of expression between wild type and MBD2 knock-out
erythroblasts: MAPK3, JunD1, and Baf57. These genes were also located in hematologic
pathways. Given that these genes were not validated, but TZFP was validated provides
further evidence that TZFP may be involved in MBD2 mediated y-globin repression.
The results of the microarray analysis provided the opportunity to search for
potential positive controls for MBD2 ChIP analysis in mouse erythroblasts. Previously,
MBD2 had only been shown to be recruited to the IL-4 locus in mouse Thl and Th2 cells
(Hendrich et al., 2001). No previous work has shown in vivo occupancy of MBD2 in
erythroid cells. Interestingly, the IL-4 gene was not detected in the microarray analysis
likely owing the lymphoid-specific factors being necessary for its expression. However,
microarray analysis and real-time PCR indicate the gene Ugt8 is up-regulated in MBD21- erythroid cells. Furthermore, ChIP experiments show this gene to be enriched at the
b

CpG island region of the Ugt8 gene thus establishing a positive control. This result
confirmed that MBD2 does not bind directly to the y-globin promoter region to mediate
transcriptional repression. Thus, it is highly likely MBD2 is negatively regulating a gene
in trans that when activated results in expression of the normally silent y-globin gene, for
example TZFP.

The mice used in this analysis were bred on a heterologous background. As a
result, the results shown here may result in false negatives due to background modifiers.
Thus, the gene responsible for the up-regulation of the y-globin gene may not be found
using this technique with these samples. False positives would likely be eliminated by
multiple repetitions in different progeny. In addition, the spleens used in this study are
highly erythroid in composition, but are not 100% erythroid. It is possible the genes
analyzed are from lymphoid cells and that induction of these genes in erythroid cells may
have no bearing on y-globin gene expression. However, we hypothesized the effect seen
may be'due to secretion of a cytokine or some other factor from a non-erythroid cells to
mediate up-regulation of the y-globin gene. A final factor to consider in the microarray
analysis is that erythroid cells are present at all stages of differentiation in the anemic
spleen. The gene responsible for the phenotype may only be differentially regulated at a
distinct stage of erythroid maturation. If this is the case, the gene will likely be difficult to
identify amidst other erythroid cells and lymphoid cells which compromise the anemic
spleen. To eliminate these variables, the MBD2-I- and MBD2+/+ mice must be bred into
the same genetic background and the microarray repeated. In addition, it may prove
necessary to isolate erythroid cells and erythroid cells from specific stages of
differentiation from the contaminating lymphoid cells to correctly identify candidate
genes. However, overexpression of candidate genes in MEL cells containing human
chromosome 11 or m A C transgenic mice would allow one to assess the effect of the
candidate gene(s) on y-globin gene expression. These initial microarray studies have

provided a dearth of information, but care must be taken when identifying candidate
genes to incorporate all possible modifying variables.
Lastly, MBD2 may be regulating a gene that results in increased levels of y-globin
by a mechanism other than via increased transcription. For example, a protein that
stabilizes y-globin mRNA or increases its export from the nucleus may account for the
increased levels of y-globin mRNA. However, unless these factors are specific for the yglobin gene, more genes should have been up-regu1ated.h the microarray analysis.
Lastly, the increased enrichment of TriMeK4 in MBD2 null PYAC transgenic mice
suggest the mechanism is transcriptionally related.

Chapter 5: Loss of MBD2 in other Erythroid Models

Introduction
We have shown that loss of MBD2 leads to expression of the y-globin gene in two
lines of adult PYAC transgenic mice. The lack of a severe phenotype in MBD2-I- mice
makes this protein a potential target for therapeutic induction of the y-globin gene for
patients suffering hemoglobinopathies (Hendrich et al., 2001). In addition, MBD2 has
been shown to inhibit tumor suppressors in cancer; therefore, compounds inhibiting
MBD2 activity may have potential benefits to cancer patients (Magdinier and Wolffe,
2001). However, loss of MBD2 must be shown to induce y-globin in other systems to
show the effect seen in transgenic mice is conserved and thus a viable target to pursue.
A cell culture model would be an ideal system to study this effect. Cell culture has
the advantage of generating large amounts of material to analyze in a relatively short
period of time. In addition, generation of transgenic cells lines is much more rapid than
generation of transgenic mice. For analysis of potential candidate genes generated from
microarray studies, a cell culture model has the benefit of allowing relatively rapid
analysis of gene overexpression or knock-down using siRNA. To this end, we are using
the mouse erythroleukemia (MEL) cell line. MEL cells are virally transformed cells
maintained at the proerythroblast stage of differentiation. However, upon chemical
treatment, these cells can be terminally differentiated into adult erythroid cells. Upon

induction, these cells express high levels of adult globin transcripts. These cells provide a
cell culture model with which to study the endogenous mouse globin genes in adult
definitive cells. In addition, these cells have been used to study embryonic and fetal
regulatory elements (Wandersee et al., 1996). MEL cells have also been created that
contain the entire human chromosome 11 by using cell fusion (Forrester et al., 1990).
These cells mimic adult erythroid cells in that they predominantly express the P-globin
gene. MEL cells containing human chromosome 11 express the y-globin upon treatment
with 5-azacytidine (Ley et al., 1984). Thus, MEL cells containing human chromosome 11
(N-MEL) behave similarly to m A C transgenic mice and human patients.
Another model system employed is the differentiation of human hematopoietic
stems cells (HSC) down the erythroid pathway. Human HSCs express high levels of the
glycoprotein CD34. As these cells differentiate they lose expression the CD34 surface
marker. CD34+ cells are capable of initiating long-term hematopoiesis both in vitro and

in vivo. CD34+ cells can be found in bone marrow, mobilized peripheral blood, cord
blood, and the fetal liver. When grown in the right mixture of chemicals and cytokines,
these cells can differentiate into cells of any hematopoietic lineage. Numerous studies
have demonstrated methods for differentiation of CD34+ cells down the erythroid
pathway (Bhanu et al., 2004; Fibach et al., 2003; Migliaccio et al., 2002). This system has
the benefit of using human cells. However, these cells are not immortal and selection of
transfected constructs is difficult to accomplish. Thus, to insert foreign DNA sequences
these cells must be infected with viruses carrying the DNA of interest. Lentiviruses have
been used to successfully transduce human CD34+ cells (Gimeno et al., 2004).

The goal of these model systems is to first recapitulate the effect seen in PYAC
transgenic mice in a cell culture system. The reason for this is two-fold. First,
demonstrating the phenotype in multiple systems suggests the effect is evolutionarily
conserved and not unique to the PYAC model. As a result, MBD2 becomes a potential
target for manipulating HbF levels in patients with hemoglobinopathies. Second, the cell
culture system is much more conducive to validating potential candidate genes generated
from microarray analysis. Validating candidate genes through gene over-expression and
siRNA knock-down is much more efficient than generating transgenic and knock-out
mice. Thus, additional model systems are needed for proof of principle as well as further
dissecting the exact mechanism of MBD2 mediated y-globin transcriptional repression.

Methods

Culture and analysis of N-MEL cells
N-MEL cells were a generous gift from Dr. M.A. Bender (Fred Hutchinson
Cancer Research Center, Seattle, Washington) (Forrester et al., 1990). Cells were
maintained in DMEM supplemented with 10% heat inactivated fetal bovine serum and
grown at 37' C and 5% COz. The human chromosome 11 does not have a selectable
marker and the cell eventually loses the chromosonle with culture. In order to keep a high
percentage of N-MEL cells, the cells were periodically purified using an antibody
directed against a cell surface marker expressed from the human chromosome, UME7. 12 x lo8 cells were spun down and resuspended in 500 pL of UME7 anti-serum. The cells
were then incubated at room temperature for 15 minutes. The cells were washed in 15 mL

PBS/2% FBS11 mM EDTA and spun at 1000 x G. The cells were resuspended in PBSl2%
FBSll mM EDTA to 1-2 x108 cellslmL. FITC conjugated goat anti-mouse antibody (MP
Biomedicals) was added to 3 pg/mL. The cells were allowed to incubate for 15 minutes at
room temperature. The cells were washed again with 15 mL PBS/2%FBS/lmM EDTA
and resuspended to 1-2 x 1o8 celllmL in a 5 mL Falcon Polystyrene tube. Anti-FITC
antibody (Stem Cell) was added at 100 pL per 1 niL of cells and allowed to react for 15
minutes at room temperature. Magnetic nanoparticles (Stem Cell) were added at 50 pL
per mL of cells and allowed to react for 10 minutes. After incubation, the volume was
increased to 2.5 mL with PBS/2%FBS/1 mM EDTA and placed in an EasySep Magnet
(Stem Cell) for 5 minutes. The supernatant was then decanted and the tube removed from
the magnet. The cells were resuspended in 2.5 mL of PBS/2%FBS/ 1 mM EDTA and
placed back in the magnet for 5 minutes. This process was repeated for a total of three
magnetic purifications. After the final wash, the cells were resuspended in normal
medium and allowed to grow.
After purification, N-MEL cells were tested for their ability to express the human
globin genes. Cells were treated for 3 days in the presence of 2% DMSO or not treated.
RNA was isolated using Trizol, DNase I treated, and reverse transcribed as described
earlier. Expression of human y-globin and P-globin transcripts was determined using realtime PCR.

ChIP Assay wilh N-MEL cells

The ChIP assay was performed essentially as described in Chapter 2 with the
following changes. Each IP was performed with -6 x lo6 cells.

Treatment of N-MEL cells with 5-azacytidine
N-MEL cells were plated at a density of 3 x 1o6 cells per 10mL medium. Cells
were treated with 2.5 pM 5-azacytidine (Sigma) for 2 days. Every 24 hours the cells were
spun down and replaced with fresh medium and 5-azacytidine. On the third day, the cells
were treated with 5-azacytidine at a concentration of 9.82 pM. The cells were harvested
48 hours later. Another set of cells was treated 24 hours after dilution with 2% DMSO.
Another set of cells was treated with 2.5 pM 5-azacytidine for 24 hours, the cells spun
down and resuspended in fresh medium containing 2% DMSO. Finally, a group of cells
was left untreated.
RNA was isolated from cells using Trizol as described earlier. The RNA was
DNaseI treated and reverse-transcribed. Analysis of y-globin gene expression was
determined using real-time PCR.

Cloning a mouse MBD2 shRNA
The sequence for mouse MBD2 mRNA (GeneBank ascension NM-0 10773) was
analyzed using three different web-based siRNA design programs: Ambion
(www.ambion.com), Qiagen (www.qiagen.com), and IDT DNA Technologies
(www.idtdna.com). Three siRNAs present in all three analyses were used. To generate a
shRNA expressing vectors, the siRNAs from the analyses were fitted with a loop

sequence and compatible ends for cloning into the EcoRI and XbaI site of the psuperior
vector. The psuperior vector was cut with EcoRI and XbaI at 37" C for 2 hours followed
by heat inactivation of the enzymes at 65" C for 20 minutes. The cut plasmid was gel
purified on a I % agarose gel using the Qiagen gel extraction kit (Qiagen). Oligos
corresponding to the three siRNAs of interest were ordered as oligos from IDT DNA
Technologies. The oligos were ordered as top and bottom strand and left and right half.
The top and bottom of each half were phosphorylated with T4 polynucleotide kinase at
37" C for 40 minutes. The enzyme was inactivated by heating at 65" C for 15 minutes.
The oligos were annealed by boiling for 5 minutes followed by gradual cooling to room
temperature to make a dsDNA at 5 pmol/pL. The ligation was performed in two steps.
First, 1 pL of the left half dsDNA was added to 36 ng of cut and purified psuperior. The
fragments were ligated with T4 ligase in a volume of 20 pL at room temperature for 3
hours. Afterwards, 1 pL of pellet paint (Novagen) was added and the DNA ethanol
precipitated at -20" C for 30 minutes. The DNA was spun and the pellet washed in 70%
ethanol. The pellet was resuspended in 20.5 pL water. The second ligation was performed
by adding 1 pL of the right dsDNA and T4 ligase in a volume of 25 pL at room
temperature for 2 hours. Alpha-Select Bronze Efficiency cells (Bioline) were transformed
with 5 pL of ligation product. Colonies were screened for clones containing the insert.
Positive clones were then sequenced to confirm the presence and sequence of the insert.
The list of oligos used for cloning is located in Table 13. The cloned siRNAs were
labeled as pSuperior30,45, and 95.

Oligo N a m e

Sequence
GATCCTGAACAACCACGTCAGCTT
CTCTTGAAAAGCTGACGTGGTTGTTCAG

TTCAAGAGAAAGCTGACGTGGTTGTTCATTTTTTC

TCGAGAAAAAATGAACAACCACGTCAGCTTT

GATCCAGGTAGCACTTACGTGAAA
CTCTTGAATTTCACGTAAGTGCTACCTG

TTCAAGAGATTTCACGTAAGTGCTACCTTTTTTTC
TCGAGAAAAAAAGGTAGCACTTACGTGAAAT

GATCCGGGTAAACCAGACCTGAAC
CTCTTGAAGTTCAGGTCTGGTTTACCCG
TTCAAGAGAGTTCAGGTCTGGTTTACCCTTTTTTC

TCGAGAAAAAAGGGTAAACCASGACCTGAACT
Table 13: Oligos used to generate M B D ~shRNA constructs.

Transfection of shRNA constructs into N-MEL Cells
Each siRNA vector (4.5 pg) was diluted to 250 pL with Opti-Mem (Invitrogen)
and lightly vortexed. Lipofectamine 2000 (10 pL) (Invitrogen) was diluted to 250 pL in
Opti-Mem, vortexed lightly, and incubated at room temperature for 5 minutes. The DNA
mixture and Lipofectamine mixture were combined, vortexed gently and incubated at
room temperature for 20 minutes. This mixture was then added to 2 mL of magnetically
purified N-MEL cells and grown overnight at 37' C in 5% C02. After 24 hours, the cells
were split and diluted 1: 10 (final volume 5 mL) in DMEM and grown for 24 hours at 37'
C in 5% C 0 2 .48 hours after transfection, G418 (Invitrogen) was added to the medium at
1 mg/mL to select for transfected cells. After selection, a pool of transfected cells was
generated. From this pool, single cell colonies were grown. These single cell clones were
screened for expression of MBD2 by real-time PCR and Western Blot. The list of primers
used for real-time PCR to assay for transcript level is located in Table 14.

Western Blot
Nuclear extracts were prepared by the Dignam method (Dignam et al., 1983).
Protein samples were run on 10% Tris-glycine SDS-PAGE ReadyGels (Bio-Rad) in
Running buffer (25 mM Tris-HC1 pH 8.3, 192 mM glycine, 0.1% SDS). The gel was
equilibrated in Transfer buffer (25 mM Tris-HC1 pH 8.0, 192 mM glycine, 20%
methanol) and then transferred to activated PVDF overnight at 30V. The next day the
membrane was washed twice for 10 minutes with l x PBS and .then blocked for 1 hour at
room temperature with rocking in 10 mL MPBST (5% (wlv) non-fat milk, l x PBS,

Primer

Sequence

mMBD2-1757-F-73

TTTATAATAGCAAGCAGGGCCCTTCCGGTG
GGGAAACTTATTTGGTACTCCTGATCTGT

mMBD2- 1757-R-215

CAAATTCACGAACCACCCGAGCAA
mMBD2- 1061-F-49

TGATGCGCTAAGTCCTTGTAGCCT
mMBD2- 1061-R- 157

TTGACTTCAGGACCGGCAAGATGA
mMBD2-93 8-F- 15

GGCAATGTTGTGTTCAGGTCTGGT
mMBD2-93 8-R- 129
Table 13: Primers used to analyzed transcript levels in N-MEL cells transfected with
MBD2 shRNA vector.

0.05% Tween-20). The blocking solution was removed and the primary antibody, antiMBD2 (Upstate) was incubated with the membrane at 3 pg/mL for 2 hours at room
temperature with rocking in MPBST. This solution was removed and the membrane
washed three times with 10 mL PBS-T for 5 minutes. The secondary antibody was then
incubated with the membrane for 1 hour at room temperature with rocking in MPBST.
This solution was removed and the membrane was washed three times with 10 mL PBST for 5 minutes and one time with 10 mL PBS-T plus 0.1% Triton-X 100. Bands were
visualized with ECL Plus (Arnersham Phannacia) and exposed to film. The blot was
stripped by incubating in 100 mM 2-mercaptoethanol, 2%SDS, and 62.5 mM Tris-HC1
ph 6.7 at 50" C for 30 minutes. The blot was washed in PBST and re-probed as above
using an anti-pactin antibody (Sigma).

Isolation and Differentiation of human CD34+ Cells
CD34+ cells were isolated from two sources: cord blood and aphaeresis pack.
Aphaeresis packs were obtained from the VCU Bone Marrow Transplant Lab. The pack
was thawed at 37" C until it became slushy, at which time thawing was completed at
room temperature. Cord blood was obtained from the VCU department of Obstetrics and
used within 24 hours of collection. The cells were diluted with an equal volume of
PBS/2% FBS. 30 mL of cells was loaded onto 15 mL of Ficoll Paque Plus (Stem Cell)
and spun at 400 x G for 30 minutes with no brake. The middle mononuclear layer was
extracted, diluted to 40 mL with PBS/2%FBS/1 mM EDTA and filter through a 70 pM
nylon filter (BD Biosciences). The cells were counted, washed twice in PBS/2%FBS/l

mM EDTA, and diluted to 4 ,x 10' cell1mL in a 5 mL Falcon Polystyrene tube. Human
CD34+ positive selection cocktail (Stem Cell) was added at 100 pL per mL of cells and
allowed to incubate for 15 minutes at room temperature. Magnetic nanoparticles were
then added at 50 pL per mL of cells and allowed to react at room temperature for 10
minutes. The cells were then magnetically purified as described above except the cells
were washed 4 times. The cells were resuspended at -1 x lo6 cells per mL in
amplification medium: IMDM, 20% FBS, 10 ngImL Stem Cell Factor (R&D Systems), 1
UImL EPO (Arngen), 1 mgImL IL-3 (R&D Systems), 1o - M
~ dexamethasone (Sigma),
M estradiol (Sigma). Cells were grown for two weeks and maintained at 1 x lo6

and

cells per mL. After two weeks, cells were spun down and washed 1X with IMDM
medium and resuspended in differentiation medium: IMDM, 20% FBS, 1 UImL EPO,
and 10 ng/mL insulin (Sigma). The cells were allowed to differentiation for 5 days. After
differentiation, cells were spun down and RNA isolated using Trizol. The presence of
globin gene transcripts was determined using RNase protection assay.

Results

The N-MEL cell line does not possess a selectable marker. As a result, the cell is
prone to losing the human chromosome 11 with prolonged culture. We first had to ensure
we could maintain the cell line in culture, purify it, and determine if it was expressing the
0-globin gene. Cells were successfully grown-up in culture and MEL cells containing
chromosome 11 were enriched using an anti-serum against a chromosome 11 marker and
magnetic beads. After purification, cells were grown in culture and differentiated down

the erythoid pathway with DMSO. After three days of differentiation, RNA was isolated
and analyzed by RT-PCR. As shown in Figure 30, the N-MEL cells were actively
expressing the human 6-globin gene. A sub-set of purified cells were amplified in culture
to generate enough cells for ChIP assay. To ensure we could successfully use the N-MEL
cell line for ChIP assays, we performed a ChIP assay for TriMeK4 at the human 6-globin
locus. As shown in Figure 3 1, the human 6-globin gene is highly enriched for TriMeK4,
indicating successful application of the N-MEL cell line. In addition, the y-globin gene is
not enriched in these cells, consistent with low levels of expression (Figure 3 1).
Activation of the y-globin gene has been shown in MEL cells containing human
chromosome 11 (Ley et al., 1984). However, it is not known whether the N-MEL cells
used here express the y-globin gene after 5-azacytidine treatment. N-MEL cells were
treated with 5-azacytidine and showed a -10-fold induction in y-globin expression as
determined by real-time PCR (Figure 32). This level of induction is similar to the level
seen after treating PYAC transgenic mice with 5-azacytidine or when MBD2 has been
genetically deleted in PYAC transgenic mice. However, treatment for 24 hours prior to
DMSO induction was unable to induce expression, but was shown to induce expression
in a different MEL human chromosome 11-containing cell line (Ley et al., 1984).
However, the amount of time the cells were allowed to induce and the inducing agent
differed in these studies and may account for the variations in expression. The N-MEL
cells here were harvested four days after 5-azacytidine treatment, which may be enough
time for the cells to recover from the demethylating effects of the compound.

,
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Figure 30: Expression of the human 0-globin gene in N-MEL cells after magnetic
purification. N-MEL cells were purified magnetically using an anti-serum against a
chromosome 11 marker and magnetic beads. The purified cells were differentiation down
the erythroid pathway with DMSO and RNA analyzed using RT-PCR. Shown above are
the results of the RT-PCR analysis.
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Figure 3 1: ChIP assay with magnetically purified N-MEL cells at the human 6-globin
gene. After magnetic purification, N-MEL cells were amplified and subjected to ChIP
assay with an anti-body directed against TriMeK4 and IgG. DNA was analyzed using
real-time PCR at the human 6-globin gene and the endogenous amylase gene.

Figure 32: y-globin expression in N-MEL cells after 5-azacytidine treatment. N-MEL
cells were treated with 5-azacytidine either with or without DMSO. Expression of the yglobin gene was performed by real-time PCR relative to the GlycophorinA gene.

After establishing we could enrich for N-MEL cells after prolonged culture, we
sought to transfect these cells with a vector expressing a siFWA against mouse MBD2.
Three web-based design programs were used to identify potential siRNA sequences.
Three regions were found in all three programs and siRNA constructs were generated for
these regions and cloned into the psuperior vector. N-MEL cells enriched by magnetic
purification were transfected with all three constructs and grown in medium containing a
selection agent. After isolating a pool of transfected cells, single cell clones were isolated
and screened for MBD2 expression levels by Western blot and real-time PCR. As shown
in Figure 33, multiple clones had >90% knock-down of MBD2, while others showed
minimal knock-down. Clone 45, which showed the greatest level of MBD2 knock-down,
was selected for further studies.
Another model system we wished to employ for the study of MBD2 mediated
transcriptional repression of the y-globin gene is the human CD34+ differentiation model.
In this system, CD34+ cells isolated from human aphaeresis packs are forced down the
erythroid pathway using a cocktail of cytokines favoring this pathway. A goal we set for
this system was for y-globin expression to be very low at the end of culture (<2% of
human 6-globin). To compare expression levels, adult and cord blood CD34+ cells were
used. After isolation and differentiation of CD34+ cells, RNA was isolated and analyzed
by W A . As shown in Figure 34, erythroid differentiated CD34+ cells isolated from
adults express high levels of 6-globin mRNA and low levels of y-globin mFWA. Thus,
this culture system expresses low enough levels of y-globin that loss of MBD2 should
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Figure 33: Western blot (Top) and real-time PCR (Bottom) analysis of N-MEL clones
contain a MBD2 shRNA vector. After transfection and selection, N-MEL cells contain a
MBD2 shRNA vector were grown as single cell clones. Individual clones were screened
for expression of MBD2 by Western blot and real-time PCR.

Figure 34: RPA analysis of y-globin expression levels in erythroid differentiated CD34-t
cells obtained from adult and cord blood. CD34+ cells were isolated and differentiated
down the erythroid pathway. After differentiation, levels of y- and P-globin niRNA were
determined by RPA.

produce a measurable increase in expression. As expected, CD34-t cells isolated from
cord blood express high levels of y-globin after erythroid differentiation.

Discussion

Here we have shown the characterization of two model systems with which to
study MBD2 mediated transcriptional repression of the y-globin gene. The first system is
a mouse erythroleukemia cell line containing human chromosome 11. The chromosome
has no selectable marker and the cells have a tendency to expel the foreign DNA after
prolonged passage. We first needed to ensure these cells could be purified and maintained
in culture. Using a magnetic purification system, N-MEL cells were specifically enriched
and were shown to express high levels of the human P-globin gene. Next, we wanted to
determine whether N-MEL cells could be ChIPed using our protocol and whether they
behaved similar to adult m A C erythroid cells. The results of the ChIP assay
demonstrated that the P-globin gene region was highly enriched while the y-globin gene
was not enriched for histone H3 trimethylated at lysine 4. This result was consistent with
the results seen in the wild type PYAC transgenic mice as well as with the levels of
expression of these two genes in N-MEL cells. Additionally, N-MEL cells were treated
with 5-azacytidine to determine whether or not the y-globin gene could be induced.
Consistent with the previous data in another MEL cell line containing human
chromosome 11, 5-azacytidine led to a -10-fold induction the of the y-globin gene, a
level of induction similar to PYAC mice treated with 5-azacytidine (Ley et al., 1984).
However, pre-treatment with 5-azacytidine followed by DMSO induction was unable to

induce expression. However, these cells were harvested four days following 5azacytidine treatment. This may have been enough time for effects of demethylation to be
reversed, or 24 hours of treatment may not be long enough to induce y-globin expression
in N-MEL cells.
Taken together, these results indicate that N-MEL cells may be a good model
system in which to study MBD2 mediated repression of the y-globin gene. These cells
appear to behave very similarly to adult m A C erythroid cells. As a result, N-MEL cells
were transfected with a construct generating a siRNA against murine MBD2. Analysis of
these cells identified multiples sub-lines with >90% knock-down of MBD2 mRNA and
protein levels. Due to the long selection time following siRNA transfection, the pool
likely has lost chromosome 11 in many cells. As a result, the cells were grown and
magnetically purified. Hemizygous MBD2 m A C transgenic mice do not show any
significant increase in y-globin expression relative to wild-type mice. Thus, we postulated
that it would take nearly 100% knock-down of MBD2 to mirror the phenotype seen in
MBD2 null transgenic mice. These cells have a dramatic knock-down of MBD2 and
should express the y-globin gene if the effect is cell autonomous.
Since N-MEL cells appear to accurately mimic adult PYAC erythroid cells, this
system will be very useful for testing candidate y-globin regulators determined from
microarray analysis. We have shown that these cells can be transfected and can knockdown gene expression using siRNA. As a result, these cells can be used to test candidate
genes. For example, adult MBD2-1- erythroid cells express a high level of TZFP. An
expression plasmid can be used to over-express this gene in N-MEL cells to determine

whether it induces y-globin expression. The converse also applies to genes downregulated in the absence of MBD2; siRNA vectors to these genes can be generated and
used to knock-down the gene to determine whether the y-globin gene is up-regulated.
Overall, the N-MEL system has the potential to be a very valuable and powerful system
with which to study MBD2-mediated transcriptional repression of the y-globin gene.
The other model system explored here was the erythroid differentiation of human
CD34+ cells. We have shown successful differentiation of adult and cord blood derived
CD34+ cells down the erythroid pathway. In addition, we needed to ensure the level of yglobin expression in adult derived erythroid cells was low. Given the high level of
transcription of the 0-globin gene, there may be a level of y-globin expression that cannot
be exceeded without first down-regulating ,6-globin expression. The main goal of this
model system is to determine whether MBD2 knock-down results in increased y-globin
expression in a human model system. If this can be shown, the potential exists that
MBD2 may be a target for pharmacological induction of HbF. Thus, we needed to
determine .the level of y-globin expression in adult erythroid cells. There was no
detectable y-globin expression in adult erythroid differentiated CD34+ as determined by
RNase protection assay. This result indicates that if MBD2 is playing a similar role in
human cells, knock-down of the gene may lead to a detectable increase in y-globin
expression. Now that y-globin levels have been shown to be barely detectable, the next
step is to transduce CD34+ with an MBD2 siRNA followed by differentiation and globin
expression analysis.

Chapter 6: Summary and Future Directions

The genes of the human 6-globin locus undergo a switch in expression during
development. During this sequential process, the 5' gene in the cluster is silenced while
the immediate 3' gene(s) becomes active. Thus, the genes are expressed in the order in
which they lie on chromosome 11: 5'

6 , y,

and 6 3'. The silencing and activation of the 6-

type globin genes involves conserved mechanisms in addition to unique mechanisms for
each gene. For example, each gene requires the LCR for high level expression. On the
other hand, the 0-globin gene requires the transcription factor EKLF while the E - and yglobin do not require it for expression (Nuez et al., 1995; Perkins et al., 1995). The exact
mechanism for globin gene switching is not fully understood, but it has been shown to
involve many interdependent processes including cis elements, trans factors including
tissue specific factors, developmental specific factors and ubiquitous factors, and
epigenetics. Our lab has a particular interest in the latter mechanism, epigenetics.
Epigenetic mechanisms result in heritable changes in gene transcription that do
not alter DNA sequence. A prototypical epigenetic modification is the addition of a
methyl group to the 5' position of cytosine in the context of the CpG dinucleotide.
Increased levels of DNA methylation are associated wi.th decreased transcription, a

correlation first noted in the P-globin locus (McGhee and Ginder, 1979). Since that time,
DNA methylation has been shown to play a part in P-type globin gene regulation in many
different model systems and inhibition of DNA methylation by the con~pound5azacytidine has been shown to activate silenced globin genes in model systems and
patients with hemoglobinopathies (Atweh et al., 2003; Charache et al., 1983; DeSimone
et al., 1982; Ginder et al., 1984; Ley et al., 1982; Ley et al., 1983; Ley et al., 1984; Pace
et al., 1994; Zucker et al., 1983). The mechanism by which DNA methylation mediates
transcriptional silencing was fostered by the discovery of a family of proteins that
specifically bind to methylated DNA. Furthermore, the proteins were shown to bind as
large complexes containing transcriptional repressive proteins. One such protein, MBD2
was shown to bind to a methylated p-globin construct as part of a large complex (Singal
et al., 1997; Singal et al., 2002). This complex was further purified from primary
erythrocytes and shown to contain MBD2. Finally, MBD2 was shown to bind to the pglobin proximal transcribed CpG islands in vivo (Kransdorf and Ginder, 2004).
We sought to determine the impact MBD2 on the regulation of the human
embryonic and fetal globin genes. Mice transgenic for different human @-typeglobin
constructs were utilized as a model system. Mice containing the entire P-globin locus as a
yeast artificial chromosome were the model system used to study regulation of the yglobin gene. Similar to results published with a different line of PYAC transgenic mice,
we observed activation of the y-globin gene in adult mice upon treatment with the
compound 5-azacytidine (Pace et al., 1994). DNA methylation and MBD2 have been
shown to, in part, mediate the silencing of the avian embryonic p-globin gene (Ginder et

al., 1984; Singal et al., 1997; Singal et al., 2002). PYAC transgenic mice were bred with
mice null for MBD2 to generate transgenic knock-out mice. Adult PYAC transgenic mice
lacking functional MBD2 express mRNA from the normally quiescent y-globin gene.
Loss of MBD2 leads to a 10-20 fold induction of y-globin mRNA in two different PYAC
transgenic mouse lines. This effect appears to be very specific as PYAC mice
hemizygous and homozygous for MeCP2, another MCBP, do not show the same effect.
Furthermore, the endogenous embryonic mouse globin transcripts are not increased in the
absence of MBD2. The impact of MBD2 loss on y-globin expression is not only seen in
adult mice, but also during development. Embryos null for MBD2 at 14.5dpc and
16.5dpc express the y-globin gene at higher levels than wild-type embryos. MBD2 is
needed to maintain y-globin gene repression in adult mice and is necessary for
developmental silencing. The increased expression of the y-globin gene in adult mice is
due to expression of the gene during definitive erythropoiesis rather than a reactivation of
embryonic erythropoiesis as the level of A y/AytGy is consistent with the ratio seen in adult
human F-cells.
It is hypothesized that epigenetic modifications beget other epigenetic
modifications to impart transcriptional silencing. For example, it has been shown .that loss
of a histone methyltransferase leads to decreased levels of DNA methylation (Tanlaru
and Selker, 2001). To determine precisely how MBD2 mediated a repressive effect on yglobin transcription, we first looked for changes in DNA methylation around the y-globin
promoter. In adult mice, the y-globin promoter and proximal transcribed region are highly
methylated while treatment with 5-azacytidine leads to -50% decrease in DNA

methylation levels and a concomitant increase in y-globin transcription. If MBD2 binding
to the y-globin promoter region results in subsequent recruitment of DNMT, DNA
methylation levels should be significantly decreased around the y-globin promoter in the
absence of MBD2. However, DNA methylation levels around the y-globin promoter are
only modestly decreased to -75% of wild-type levels in MBD2 null mice. Thus it seems
unlikely MBD2 is recruiting DNMT to the y-globin promoter region and more likely that
instead the modest decrease in DNA methylation around the y-globin promoter is due to
increased transcription of the gene. We next determined what impact loss of MBD2 has
on post-translational histone modifications around the y-globin gene. Not surprisingly,
histone H3 trimethylated on lysine 4 was enriched -4-fold in knock-out mice versus
wild-type mice. This modification is associated with active transcription, indicating the
increase in y-globin expression is due to increased transcription of the gene. On the other
hand, no significant difference was seen in the levels of acetylated histones H3 and H4
between wild-type and knock-out mice. These data indicate that MBD2 is not recruiting
HDACs to the y-globin gene region due to the lack of increase in enrichment of
acetylated histones H3 and H4 in MBD2 null mice. Adult MBD2 null OYAC transgenic
mice and D A C mice treated with 5-azacytidine express the y-globin gene at similar
levels. To determine whether MBD2 and 5-azacytidine function in the same pathway(s),
MBD2 null and wild-type PYAC transgenic mice were treated with 5-azacytidine to
compare levels of induction of the y-globin gene relative to pre-treatment levels. The
nominal additive induction of the y-globin gene in MBD2 null mice treated with 5-

azacytidine suggests that both MBD2 and 5-azacytidine are working chiefly along the
same pathway(s).
We next explored the role of DNA methylation and MBD2 on the regulation of
the embryonic e-globin gene. To study human e-globin regulation, transgenic mice
containing the entire sequence from 5' of HS5 through 4 and 12kb 3' of the e-globin
polyA site were generated. Similar to results with other human e-globin gene transgenic
mice, these mice show correct developmental silencing of the transgene during
development: high expression in the 10.5 dpc yolk sac and low to no expression in the
14.5 dpc fetal liver and adult erythroid cells. Three lines were used in the studies: two
28kb lines and one 36kb line. Adult mice from all three lines effectively express the
normally silenced transgene upon a 5-day treatment course with 5-azacytidine. 28kb
LCRe transgenic mice show high levels of DNA methylation around the promoter and
proximal transcribed region in adult erythroblasts (>go%) and low levels of DNA
methylation in 10.5dpc yolk sacs (<40%). The level in the yolk sac is likely to be even
lower than calculated, due to contaminating epithelial cells. Treatment with 5-azacytidine
reduces the level of DNA methylation -20%. This modest decrease in DNA methylation
is likely a copy number effect as not all copies of the transgene may be equally
demethylated. In contrast to the results in human e-globin construct mice, in the context
of mice containing the entire 0-globin locus as a yeast artificial chromosome transgene,
the e-globin gene is expressed at a much lower level upon 5-azacytidine treatment.
Similar to the results seen with 5-azacytidine, adult 28kb LCRE lines 1 and 2 express the
transgene when they are null for MBD2. Once again, PYAC mice do not express high

levels of .the c-globin gene in the MBD2 null background. f l A C mice lacking MBD2
express the y-globin gene at a level commensurate with wild-type mice treated with 5azacytidine. One line of 28kb LCRc transgenic mice expresses the c-globin gene at higher
levels in the MBD2-I- background than upon treatment with 5-azacytidine. This result
seems to indicate a possible position effect of the transgene rendering them more
sensitive to changes in epigenetic status than f l A C transgenic mice. The c-globin gene
has been reported to be silenced by a process termed autonomous silencing whereby the
promoter and 5' flanking region of the gene contain all elements necessary for correct
developmental silencing in the absence of other P-type globin genes competing for
enhancer activity (Raich et al., 1990; Shih et al., 1990). On the other hand, the y-globin
gene has been shown to be silenced by a combination of autonomous silencing and
competition with the P-globin gene for the enhancer activity of the LCR (Behringer et al.,
1990; Dillon and Grosveld, 1991; Enver et al., 1989; Enver et al., 1990). These results
indicate that the c-globin gene can be activated upon 5-azacytidine treatment or in the
MBD2-I- background, but it remains highly repressed under the same conditions when
other globin genes are present. Therefore, it appears that a combination of 5' cis sequence
mediated autonomous silencing, LCR competition, and DNA methylation contribute to
maintain the lo4 level of silencing of the c-globin gene in adult erythroid cells.
To determine the exact mechanism of DNA methylation and MBD2-mediated
repression of the E - and y-globin genes, ChIP assays were perfomled to determine
whether MBD2 was bound to the promoter region of either gene. MBD2 does not
associate with the y-globin promoter in either MBD2+/+ or MBD2-1- mice. However,

MBD2 does associate with the Ugt8 CpG island, the upstream GATA2 promoter, and the
CpG island 3' of the TZFP gene in MBD2+/+ but not MBD2-1- mice indicating the
specificity of the antibody and validity of the assay. These results indicate that MBD2
mediated transcriptional silencing of the y-globin gene is not due to the direct binding of
MBD2 to the promoter region of the y-globin gene. MBD2 is likely repressing a gene in
trans that when expressed induces transcription of the y-globin gene. In an effort to

determine what gene(s) MBD2 may be regulating, a microarray analysis was performed
on splenocytes from MBD2 wild-type and knock-out mice. The initial analysis of upregulated genes failed to identify an erythroid specific transcription factor. However,
after analyzing the data set using a pathway analysis program, a group of genes from
known hematopoietic pathways were identified. Validation of potential candidate genes
revealed TZFP as a candidate. The expression of this gene is increased -30-fold in
MBD2 null erythroid cells. In addition, TZFP interacts with GATA2, a protein shown to
increase transcription of the y-globin gene upon over expression (Ikonomi et al., 2000;
Tsuzuki and Enver, 2002). While the nature of this interaction is not known, TZFP is
currently a lead candidate for future analysis.
Through the course of these studies, it was revealed that MBD2 is necessary for
silencing the y-globin gene in adult PYAC transgenic mice and during development. The
effect of MBD2 on y-globin is very specific, as no other embryonic globin genes are upregulated in its absence nor was loss of another MCBP able to recapitulate this
phenotype. Absence of MBD2 is associated with modest changes in DNA methylation
and histone acetylation around the y-globin gene, but the increased level of transcription

is associated with an increase in trimethylated histone H3 lysine 4. MBD2 is not
mediating its repressive effect at the y-globin promoter region as MBD2 did not CliIP to
the y-globin promoter region. The phenotype observed is likely due to MBD2 mediated
repression of a y-globin activator(s) of which TZFP has been identified as a potential
candidate. Taken together, we believe MBD2 is repressing a gene that when activated
either directly or indirectly activates y- and c-globin transcription (Figure 35). Finally,
inhibition of DNA methylation and loss of MBD2 revealed a competitive silencing
mechanism for maintaining c-globin transcriptional repression. In the absence of other
globin genes, loss of MBD2 and 5-azacytidine each led to expression of the c-globin gene
in adult mice. However, these same conditions fail to induce significant expression of the
c-globin when other @-typeglobin genes are present on the transgene.
In order to fully understand how MBD2 mediates y-globin transcriptional
repression more work must be performed. One obvious place to begin is to determine
whether the effect seen is unique to the mouse model utilized. N-MEL cells provide an
opportunity to determine whether the effect can be seen in a cell culture system. N-MEL
cells are a hybrid cell line in which normal mouse erythroleukemia cells contain a copy
of human chromosome 11. These cells have been shown to express the @-typeglobin
gene in a pattern similar to that seen in adult PYAC transgenic mice: high levels of @globin and low levels of y-globin mRNA (Forrester et al., 1990). N-MELs, and a similar
cell line containing human chromosome 11 were shown to increase expression of the yglobin gene upon treatment with 5-azacytidine (Ley et al., 1984). Thus, this system in
essence mimics adult PYAC erythropoiesis. Since cells in culture can be transfected with

Unknown gene

y - or c-globin gene
Figure 35: Model for MBD2 mediated transcriptional repression of the human -y- and t globin genes. In adult mice, MBD2 silences and unknown gene (?). In the absence of
MBD2 or upon treatment with 5-azacytidine, this gene becomes expressed and either
directly or indirectly activates transcription of the human y- or e-globin genes.

constructs producing shRNA to downregulate the target genes, the phenotype can
potentially be reproduced in another system, adding more credibility to the results
presented here. Further proof can be provided using erythroid differentiation of human
CD34+ cells. CD34+ cells can be cultured and induced down the erythroid pathway to
express globin genes (Bhanu et al., 2004; Migliaccio et al., 2002). We have shown that
CD34+ cells obtained from adult and cord blood can be differentiated into erythroid cells.
In addition, CD34+ cells from cord blood express high levels of y-globin niRNA while
those derived from adult blood show <2% y-globin mRNA. As a result, this system has
the potential to study the effect of MBD2 loss in human primary cells. CD34+ cells have
shown the ability to be transduced by lentiviral vectors encoding shRNAs (Hong et al.,
2005). In addition, a human siRNA for MBD2 has been described (Lin and Nelson,
2003). Transducing adult CD34+ cells with a lentiviral vector containing an MBD2
shRNA followed by erythroid differentiation would be a valuable approach to obtain data
to strengthen the argument that MBD2 mediates y-globin transcriptional repression in a
variety of model systems. If these data can be obtained, the potential then exists for
MBD2 to be a target protein for therapeutic induction of fetal hemoglobin.
MBD2 appears to be necessary, at least in part, for the developmental silencing of
the y-globin gene. The potential exists that the effect seen in adult PYAC transgenic mice
lacking MBD2 is due in some way to the absence of the protein during development. In
this case, induction of y-globin by inactivation of MBD2 in adult erythroid cells may not
be occur if MBD2 is present during development. The N-MEL system and CD34+
culture systems described above would help counter this argument as these cells have

always possessed functional MBD2. However, to test this in vivo, a conditional MBD2
knock-out must be produced. To perform this, the MBD2 gene must be surrounded by
loxP sites so that upon activation of Cre recombinase, the gene will be removed. The
conditional knock-out can be performed in a variety of ways. Placing a Cre-transgene
under the control of the 0-globin gene promoter would allow removal of the gene at an
earlier time point, however the 0-globin gene begins to be activated around the time
primitive erythropoiesis ends and thus does not allow for adult excision of the gene.
Placing the Cre-gene under the control of the Tet-repressor would allow for chemical
induction of cre expression upon treatment with tetracycline. This system would allow
for analysis of transgenic mice that possess MBD2 during development and have only
lost the gene as adults. This mouse model would allow one to assess the importance of
MBD2 expression during development on y-globin activation in adult mice via MBD2
elimination.
One theory for the activation of globin genes upon treatment with 5-azacytidine is
that the cytotoxic nature of the drug accelerates the differentiation of an erythroid
progenitor. Adult erythroid cells early in the differentiation pathway have been shown to
express the y-globin gene (Stamatoyannopoulos, 2005). Along this line, MBD2 loss may
lead to an increase in the number of erythroid progenitors or may favor erythroid
differentiation of hematopoietic stem cells. The increased number of erythroid cells may
overwhelm the bone marrow leading to a situation similar to the cytotoxic theory where
early progenitors are forced to differentiate at an accelerated rate. In this case, the
increased number of erythroid cells would cause some early differentiating cells to

differentiate at an accelerated rate and thus still produce y-globin mRNA. To test this
theory, colony assays can be performed to determine whether bone marrow cells from
MBD2 null mice produce more erythroid colonies than wild-type bone marrow cells. In
addition, it is not yet known whether the effect of MBD2 upon y-globin expression in
adult mice is pancelluar or heterocellular. To determine this effect, an anti-fetal
hemoglobin antibody can be used on peripheral blood cells. The cells can either be scored
under a microscope or via flow cytometry to determine whether all cells or a subset of
cells express the y-globin gene.
While the initial microarray studies on MBD2+/+ and MBD2-I- mice have been
very informative, the analysis should be repeated to accoui~tfor possible confounding
elements. First, the mice used in the study were from a mixed genetic background. As a
result, potential modifier genes may not have been detected. To account for this problem,
the MBD2-I- mice can be bred into a homogeneous genetic background and the results
compared to the pilot study to identify the effects of potential modifier genes. In the
initial studies, erythroid cells were not purified out of the cell population. While l-acetyl2-phenylhydrazine treatment results in conversion of the spleen to a 3 0 % erythroid
organ, lymphocytes are still present (Spivak et al., 1973). We initially wanted to include
lymphocytes in the instance that loss of MBD2 led to cytokine release from non-erythroid
cells that induced erythroid cells to express the y-globin gene. The potential exists that
these cells are preventing the detection of a gene involved in y-globin induction or are
expressing a gene at a high level that may be interpreted as a y-globin activating gene.
Thus, the microarray analysis should be repeated after purifying erythroid cells using an

erythroid specific marker such as Ter-119. Finally, the gene(s) responsible for y-globin
expression may only be expressed during a certain phase of erythroid differentiation.
Lodish and colleagues have described a method for isolating murine erythroid cells at
different stages of erythropoiesis based on expression of the cell surface markers CD71
and Ter-119 (Socolovsky et al., 2001). Microarray analysis can be repeated on erythroid
cells from different stages of differentiation to discern whether the factor(s) responsible
for y-globin expression are expressed transiently during differentiation. Furthermore,
candidate genes from the pilot microarray study, as well as the additional studies, need to
be validated in a cell culture model (N-MEL or CD34+) or in a mouse model. If a
candidate gene is expressed highly in MBD2 null cells, the cDNA should be over
expressed in N-MEL cells to determine whether it is able to induce expression of the yglobin gene. A more ideal system, though more time-consuming and laborious, would be
to over-express the gene in D A C transgenic mice to deternine whether it can
recapitulate the effect seen in MBD2 null mice. If a candidate gene is under-expressed in
MBD2 null cells, siRNA should be performed in N-MEL or transgenic mice to determine
whether knock-down of the gene is able'to induce expression of the y-globin gene. While
the initial microarray study was very informative, more characterization must be
performed to ensure the validity of the results.
Loss of MBD2 and DNA methylation each revealed that a competitive silencing
mechanism exists for the human €-globin gene. It should be noted that the PYAC
transgene contains much more additional sequence both 5' and 3' relative to the 28kb
LCREconstruct used to generate transgenic mice. Thus, the possibility exists that other

sequences within the PYAC are responsible for the observed effect on competition. To
test this, multiple transgenic mice lines can be made. First, a line continuing the 3'
sequence through either y-globin gene can be generated. This transgene will only differ at
the 3' end of the gene and would reveal whether the presence of the y-globin promoter
can suppress expression of the €-globin gene during 5-azacytidine treatment or in the
absence of MBD2. It may be that the y-globin promoter is insufficient to maintain Eglobin repression, thus a construct continuing 3' through the P-globin gene can be
generated and assayed for its ability to prevent c-globin expression. These constructs also
contain sequence that could be confounding to the results. Thus, either the y- or 0-globin
promoter and gene could be added immediately 3' to the 28kb LCRE construct and used
to generate transgenic mice. This construct would show that all that is needed to suppress
the c-globin gene is an additional P-type globin gene and strengthen the argument that a
competitive silencing mechanism exists for the €-globin gene.
The results presented here and proposed above serve to positively impact one
group of patients directly and another group indirectly. One current therapeutic approach
for the treatment of hemoglobinopathies is through the pharmacological induction of fetal
hemoglobin. While promising results have been obtained treating patients with 5azacytidine, hydroxyurea, and short chain fatty acids, many problems still exist. These
compounds are highly toxic and not all patients respond to the therapy. In addition, most
of these agents have to be administered intravenously. As a result, a market for better
pharmacological inducers of fetal hemoglobin exists. The work described here has the
potential to lead to a new class of therapeutics, those that target MBD2. We have shown

that in the absence of MBD2, the y-globin gene is activated in adult transgenic mice. In
addition, mice lacking functional MBD2 display only 'a mild phenotype (Hendrich et al.,
2001). Thus, targeted disruption of MBD2 through binding site interaction or corepressor interaction may be less toxic than the current line of agents. At the very least, it
has shown an additional mechanism for y-globin silencing that may be beneficial at a
later date. Epigenetic regulation of transcription is not limited to the 0-globin locus.
Epigenetic modifications play a role in regulating tumor suppressor genes as well as
imprinting genes whose dysregulation can lead to disease. Thus, understanding the
mechanism of how MBD2 mediates repression in a tissue specific manner may be
beneficial to the study of other pathologies where epigenetics play a crucial role in
pathogenesis.
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